

CURRICULUM VITAE

NAME **John W. Sleasman, MD**
Professor and Chief
Division of Allergy, Immunology, and Rheumatology
Department of Pediatrics
University of South Florida College of Medicine
801 6th Street South, Box 9350
St. Petersburg, Florida 33701-4899

Telephone: 727-553-1257/727 767 4471
Fax: 727-553-1295/727 767 8542
Email: jsleasma@health.usf.edu

EDUCATION

B.S., Rhodes College with Distinction, Memphis, TN, 1970-1974

M.D., University of Tennessee, Memphis, TN, 1976-1981

Intern and Resident: Department of Pediatrics, Shands Hospital, University of Florida, College of Medicine, 1981-1985

Chief Resident: Shands Hospital, University of Florida, College of Medicine, 1984 - 1985

Clinical Fellow: Clinical, Division of Infectious Disease and Immunology, Department of Pediatrics, University of Florida, College of Medicine, 1985 -1987

Research Fellow: Division of Tumor Immunology, Dana Farber Cancer Institute, Department of Pathology, Harvard Medical School, 1987-1988

APPOINTMENTS

1984 – 1985 Instructor, Pediatrics, University of Florida, College of Medicine, Gainesville, Florida

1985 – 1987 Instructor, Surgery, University of Florida, College of Medicine, Division of Emergency Medicine

1988 – 1994 Assistant Professor, University of Florida, Department of Pediatrics, Division of Immunology and Transplantation

1992 – 1995 Division Chief, University of Florida, Department of Pediatrics, Division of Allergy and Immunology

1995 – 2002 Division Chief, University of Florida, Division of Immunology and Infectious Diseases, Department of Pediatrics

1994 – 1999 Associate Professor, University of Florida, Departments of Pediatrics and Pathology, Immunology and Laboratory Medicine

- 1999 – 2002 Professor, University of Florida, Departments of Pediatrics and Pathology, Immunology and Laboratory Medicine
- 2002 – present Robert A. Good Endowed Chair of Immunology, Department of Pediatrics, Division of Allergy, Immunology and Rheumatology, University of South Florida College of Medicine
- 2002 – present Division Chief, Department of Pediatrics, Division of Allergy, Immunology & Rheumatology, University of South Florida College of Medicine
- 2003 – present Medical Director, Children’s Research Institute Immunodiagnostics Laboratory, All Children's Hospital / University of South Florida College of Medicine
- 2004 – present Vice Chairman, Department of Pediatrics, University of South Florida College of Medicine

HONORS AND AWARDS

- 1977 Cecil M. Gooch Medical Scholarship
- 1981 NIH Medical Student Research Award
- 1982 W.P. Hadley Award, Outstanding Pediatric Intern
- 1986 Henry Kokomoor Award, Outstanding Pediatric Fellow
- 1995 Invited testimony before the United States Congress, Subcommittee on Commerce, regarding the re-authorization of the Ryan White C.A.R.E. Act, Washington, D.C.
- 1996 Selected *Best Doctors in America*, Allergy and Immunology Physicians by the **American Health Magazine**
- 1998 President, Southern Society for Pediatric Research
- 1995 Selected *Best Doctors in America: Southeast Region*
- 2001 University of Florida Clinical Science Faculty Research Award, 2001
- 1998 Selected *Best Doctors in America: Allergy and Immunology Physicians*
- 2002 Robert A. Good Endowed Chair in Immunology
- 2003 Selected *Best Doctors in America* by Best Doctors
- 2005 Selected *Top Doctors in America* by “Castle Connolly’s America’s Top Doctors”
- 2005 Selected *Best Physicians in America* by Best Doctors in America
- 2006 Silver Award for Pediatric AIDS research by Children’s Hospital of Philadelphia
- 2007 Recognized as a *2007 America’s Top Doctor* by Castle Connolly Medical Limited
- 2008 Chairman, AIDS Immunology and Pathogenesis Studies, Center for Scientific Review, National Institutes of Health
- 2008 *Tampa Bay Business Journal’s* Healthcare Heroes Award for Research and Innovation

2008 Selected *Best Doctors in America* by Best Doctors

BOARDS

Diplomat, National Board of Medical Examiners, 1982

Diplomat, American Board of Pediatrics, Certificate #37698; 1988

Diplomat, American Board of Allergy and Immunology, Diagnostic and Laboratory Immunology, Certificate #0139, 1990

Diplomat, American Board of Pediatrics,
Pediatric Rheumatology, Certificate #201106, 1994

LICENSURE

State of Florida Board of Medicine, #041090, October 18, 1982 - 2010

SOCIETY MEMBERSHIPS:

American Medical Association
Florida Medical Association
Florida Allergy and Immunology Society
Society for Pediatric Research
American Pediatric Society
American College of Allergy and Immunology
American Society for Microbiology
American Academy of Pediatrics
 Section of Infectious Diseases
 Section of Rheumatology
 Section of Allergy and Immunology

EDITORIAL BOARDS

Reviewer, *Journal of Pediatrics*, *Chest*, *Journal of Immunology*, *Pediatric Research*, *Achieves of Pediatrics*, *Annals of Internal Medicine*, *Clinical Immunology and Immunopathology* *Journal of Infectious Diseases*, *Cytometry* *Journal of Allergy and Clinical Immunology*, Associate editor, *Clinical and Diagnostic Immunology*.

UNIVERSITY COMMITTEES AND APPOINTMENTS:

Housestaff Advisory Committee, Department of Pediatrics, University of Florida, College of Medicine, 1981-1986

Housestaff Selection Committee, Department of Pediatrics, University of Florida, College of Medicine, 1983-1985

Director, Pediatric Sports Medicine Program, Department of Pediatrics, University of Florida, 1983-1985

Elected Member, University of Florida Senate, 1993-1995

Department Representative, Southern Society for Pediatric Research, 1992-1998

Appointed Member, University of Florida College of Medicine,
Promotion and Tenure Committee, 1994 – 1997

Appointed Member, GCRC Advisory Committee, University of Florida,
Shands Hospital, 1996 - present

Appointed Member, Promotion and Tenure Committee, Department of Pediatrics,
University of South Florida, 2002 – present

Chairman, Search Committee for University South Florida Transplant Cardiologist, 2007- present

Appointed Member, Molecular Medicine, 2005 - present

Chairman, Search Committee, Sam's Club Wal-Mart Chair in Pediatric Oncology, 2006 - present

EXTRAMURAL COMMITTEES AND APPOINTMENTS

Appointed Member, Florida Medical Association, Committee on AIDS, 1988 – 1992

Appointed Member, State of Florida, Department of Health and Rehabilitative Services HIV Planning Council,
1990-1994

Appointed Member, State of Florida Department of Professional Regulation, Board of Medicine, Special
Committee on AIDS, 1991 – 1995

Appointed Member, State of Florida Department of Health and Rehabilitation Services Organ and Tissue
Procurement and Transplantation Advisory Board, 1992-1994

Special Review Committee Member, National Institutes of Health, RFA-NIH-NIAID 92-AI-13, "Women and
Infants Transmission Study (WITSII), 1993.

Special Review Committee Member, Merit Review Board, Department of Veterans Affairs, 1993

Pediatric AIDS Foundation Scientific Advisory Board, 1993 – Present

ad hoc Member, Microbial Immunological Review Group, AIDS & Related Research Study, Section 1, National
Institute of Allergy and Infectious Diseases, 1994

Council Member, Southern Society for Pediatric Research, 1995 – 1997

Special Review Committee Member, AIDS Preclinical Research Review Branch Committee, National Institute of
Allergy and Infectious Diseases, RFP-NIH-NIAID-DAIDS-94-29, 1995

Member, Microbial Immunological Review Group, AIDS Related Research Study, Section 1, National Institutes
of Health, 1996 – 2000

Special Review Committee Member, National Institute of Child Health and Human Development, Special
Emphasis Panel, 1997

Member, Pediatric Primary Therapy, Research Agenda Committee, The Pediatric AIDS Clinical Trial Group,
1997-1999

Member, Pediatric Immune Based Therapy, Research Agenda Committee, The Pediatric AIDS Clinical Trial Group, 1997 – present

Invited Reviewer, University of California Statewide AIDS Research Program, 1999

Member, Protocol Evaluation Committee, The Pediatric AIDS Clinical Trial Group, 1998 –present

National Protocol Chair, Pediatric AIDS Clinical Trial Group protocol 395, A Multicenter, Open-labeled, 96-week Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Indinavir in combination with Stavudine and Lamivudine in Pediatric Patients with HIV-1 Infection, A Multicenter Trial of the AIDS Clinical Trials Group, The National Institute of Allergy and Infectious Diseases, 1998 - 2002

Consulting Immunologist, Immune Deficiency Foundation, 1998- 2002

National Protocol Co-Chair, Pediatric AIDS Clinical Trial Group protocol 402, a phase I/II Trial of Subcutaneous IL-2 with Highly Active Antiretroviral Therapy in HIV-infected children with Immunosuppression, A Multicenter Trial of the AIDS Clinical Trials Group, 2000 – present

Protocol Immunologist, Pediatric AIDS Clinical Trial Group protocol 219C, Pediatric Late Outcomes, 2000 – present

Protocol Immunologist, Pediatric AIDS Clinical Trial Group protocol 1034, Comparative Trial of Protease-Containing and Protease-Sparing HAART Regimens in HIV-Infected Adolescents, 2001 – present

Chairperson, Adolescent Research Agenda Committee, Pediatric AIDS Clinical Trial Group, 2001-2004

Member, Center for Scientific Review, Special Emphasis Panel, ZRG1 AARR-1 12, AIDS and Related Research, Study Section 1, National Institutes of Health, 2002.

Member, Center for Scientific, Review Special Emphasis Panel, ZRG1 AARR-1 (46), Innovation Grants for AIDS Research, PA02-046, PA02-073, National Institutes of Health, 2002

Member, Center for Scientific, Review Special Emphasis Panel, 1P01AI074415-01A1 Vaccine Design and Acute HIV Infection. National Institutes of Health, NIAID September 2007

Member, Center for Scientific Review, AIPS, AIDS and Immunology and Pathogenesis Studies, AARR-2V, National Institutes of Health, 2004-2008

Clinical Program Advisor, All Children's Health System, All Children's Hospital, 2002-present

Abstract Reviewer at the 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2003

Moderator, Allergy and Immunology Platform Session, Pediatric Academic Societies, 2003

Appointed member, select group of leaders of the American Medical Association/Accreditation Council for Graduate Medical Education, Chicago, Illinois, 2003 – present

Appointed associate member, Children's Oncology Group (COG), Arcadia, California, 2005

Appointed Member, Medical Staff Executive Committee, All Children's Hospital, 2006 – 2007

Consultant on Immune Deficiency Diseases, CSL Behring, 2007

Chairperson, Therapeutic Leadership Group, NICHD Adolescent Medicine Leadership Group, Adolescent Trials Network, 2001-2011

PREVIOUS RESEARCH AWARDS

National Institutes of Health Research Fellowship Award, 1985 – 1987.

Principal Investigator, American Cancer Society Institutional Research Grant, 1985 – 1986.

Principal Investigator, University of Florida, Division of Sponsored Research, New Faculty Research Award, DSR-D-79, 1989 – 1990.

Faculty Sponsor, Florida Chapter of American Cancer Society Student Research Fellowship, 1990.

Principal Investigator, University of Florida, Division of Sponsored Research, Faculty Research Award 1991-1992.

Principal Investigator, American Cancer Society Institutional Research Grant, 1991-1992.

Principal Investigator, Children's Miracle Network, Telethon Award, 1992-1993.

Faculty Sponsor, Pediatric AIDS Foundation, Research Fellowship, 1993-1994.

Principal Investigator, Children's Miracle Network, Telethon Award, 1993-1994.

Co-investigator, RO1 #HD 44719-04, Biological Implications of HIV-1 Genetic Variability, 1989-1994.

Co-principal Investigator, RO1 #HD32259-01, HIV-1 Variants within PBMC, James A. Shannon Director's Award, 1994.

Principal Investigator, Pediatric AIDS Foundation, IDNO# 5480-16-PGR, Role of Maternal Antibodies in Perinatal HIV Transmission, 1993-95.

Principal Investigator, Medimmune, Inc., Medi-493-CPO18, A Double-Blind Randomized Trial Comparing the Immunogenicity of 3 Commercial Scale Consistency Lots of GD-ALUM-MPL Vaccine, 1996-1997.

Principal Investigator, Florida Department of Health & Rehabilitation Service, Evaluation of the Impact of Maternal Screening on Perinatal HIV-1 Transmission in Florida, 1998.

Principal Investigator, SmithKline Beecham 208141-024 clinical study, A Double-Blind, Randomized Trial Comparing the Immunogenicity of 3 Commercial Scale

Consistency of GD-Alum-MPL Vaccine Containing CHO K1 GD in Healthy HSV Seronegative Adult Subjects, 1996-1999.

Principal Investigator, Kern McNeill International/Glaxo Wellcome Protocol CNA3006: A Double-Blind, Randomized, Multicenter Trial in Evaluate the Safety and Efficacy of the Combination of 1592U89/Zidovudine (ZDV)/Lamivudine (3TC) in HIV-1 Therapy Experienced Pediatric Patients, 1997-1999.

Co-investigator, NIH Grant #RO1 MH44618. HIV: Neuropsychiatric and Psychoimmune Relationships. Dwight L. Evans, Principal Investigator, 1996-2000.

Principal Investigator, Merck Research Laboratories, CRIVAN[®] (indinavir sulfate) Pediatric Study No. 068-002, A Multicenter, open-labeled, 24 week study to investigate the safety, pharmacokinetics and efficacy of indinavir in combination with stavudine and lamivudine in pediatric patients with HIV infection. 1997-2000.

Co-Investigator, NIH Grant #RO1 5545401A1. HIV in Women: Stress, Immunity and Disease Progression.

Dwight L. Evans, Principal Investigator, 1996-2001.

Principal Investigator, Pediatric AIDS Foundation #PG-50956, Impact of Age on Immune Reconstitution Following HAART, 1999 – 2001.

Principal Investigator, NICHD Pediatric and Perinatal HIV Clinical Trials Network, #NO1-HD-33162, 1996-2002.

Medical Director, Dept of Health & Rehabilitation Service - Children's Medical Services, Children's AIDS/HIV Program, 1994 – 2002.

Co-principal Investigator, University of Alabama School of Medicine, NIH-NIAID #NO1-A1-65306, Collaborative Antiviral Study with University of Alabama, 1996-2002.

Principal Investigator, Merck Protocol No.: 050-01, Comparison of the Safety, Tolerability, and Immunogenicity of P32 Process Upgrade Varicella Vaccine (PUVV) to P31 PUVV When Each is Administered Concomitantly With M-M-R™ II to Subjects 12 to 23 Months of Age, 2000-2001.

Principal Investigator, Hoffman-La Roche No.: T20-310/NV16056, A Phase I/II Pharmacokinetic and Safety Study of T-20 in Combination with an Optimized Background in HIV Infected Children and Adolescents, 2001 - 2003.

Principal Investigator, Pharmacia & Upjohn Co. Protocol No.: M/1260/0082, Linezolid IV/PO vs. Vancomycin IV for the Treatment of Resistant Gram-Positive Bacterial Infections in Children, 2001 - 2003.

Co-subcontractor, DHHS-HAB Award No. 4 U6900004-07 1, Florida AIDS Education and Training Center Network, 1992 - 2002.

Principal Investigator, Children's Miracle Network, Telethon Award, Program in Human Immunodeficiency Diseases, 2001-2002.

Principal Investigator, Bayer Corporation Study 100348 - IGIV-C 10% Rapid Infusion Trial in Primary Immune Deficient Patients, 2003 – 2004.

Principal Investigator, National Alliance for Research on Schizophrenia and Depression (NARSAD) Young Investigator's award, 2002 – 2004.

Co-Investigator, Department of Veteran Affairs, Impact of Age on Immune Reconstitution 2000 – 2005.

Principal Investigator, ZLB Behring Ag, Study ZLB02-003CR / ZLB05-006CR - A multicenter study on the efficacy, safety and pharmacokinetics of IgPro10 in patients with primary immunodeficiency (PID), 2005-2006

Principal -Investigator, All Children's Hospital Pediatric Clinical Research Center, Health Resources and Services Administration, Department of Human Services, program Development Award, R60 MC 0003 01-04 (#HRSA IC76HF00920-01) – 2003-2007

Principal Investigator, All Children's Hospital Pediatric Clinical Research Center (ACH PCRC PDA 2000) – Biological Effects of HIV-1 Genetic Variability, 2005- 2006

Co-Principal Investigator, Pediatric AIDS Clinical Trials Group (PACTG), N01-HD-3-3345 (NIH/NICHD) – 11/01/02 – 12/31/07

Co-Principal Investigator, R01 HD-32259 09-13 (NIH/NICHD) - HIV Variants within PBMC Subpopulations in Infants, 01/01/2003 – 12/31/2007

CURRENT FUNDING

<p>5 R01 AI47723-06 Sleasman PI NIH/NIAD Impact of HIV-1 Genotype on Therapy Response in Children The major goals for this project are to determine structure-function relationships between HIV-1 protease and p7^{NC} from patients treated with combination therapies that include protease inhibitors.</p>	<p>04/05/2000 – 01/31/2011 \$433,202 (annual direct costs)</p>	<p>10%</p>
<p>R01 AI065265 Goodenow PI; JW Sleasman Co-PI NIH/NICHD Role of HIV-1 Env Diversity in Cellular Tropism The goal of this research is to determine the interactions between HIV-1 envelope and CD4 target cells and consequence of viral evolution on cell tropism in HIV-infected children and adolescents.</p>	<p>04/01/2005 – 03/31/2010 \$466,484 (annual direct costs)</p>	<p>5%</p>
<p>The major goals for this project are to define interactions between HIV-1 and CD4 target cells within infected children and adolescents.</p>		
<p>2 U01 HD040433-08 CM Wilson PI; JW Sleasman Co-PI NIH/NICHD Adolescent Medicine Leadership Group (AMLG) The major goals for this project are to implement an Adolescent Medicine Leadership Group (AMLG)</p>	<p>04/26/2001 – 02/28/2011 \$4,672,128</p>	<p>26%</p>
<p>OHHI 2005 National Oceanic Atmospheric Administration (NOAA) Walsh PI; Sleasman Co-PI Effects of brevetoxin on human immune cells The overall objective of this proposed project is to understand mechanisms of Immunotoxicity resulting from brevetoxin exposure</p>	<p>10/01/2005 – 09/30/2009 \$230,623 (annual direct costs)</p>	<p>5%</p>
<p>K30 RR022270 Sleasman (Co-I) NIH/NCRR USF Scholars Inpatient-Oriented Research Program (SPOR) A multidisciplinary didactic research training program for career development of clinical investigators</p>	<p>08/01/2005 – 08/31/2010 \$300,000 (annual direct costs)</p>	<p>2%</p>
<p>State of Florida Red Tide Mitigation and Control Program Program Dorsey (PI) Sleasman (Consultant) Measurements of Airways Inflammation in Children Exposed to Red Tide</p>	<p>11/30/2007 – 6/30/2009 \$65,636 (total direct costs)</p>	<p>0 %</p>
<p>The goal of this study is to improve our understanding of the underlying mechanism of airways symptoms seen in asthmatic children during red tide exposure</p>		
<p>Pharmaceutical</p>		
<p>CSL Behring – Protocol # 05-01-I Sleasman (PI) Radiant Medical, Inc. Virtue Study</p>	<p>08/21/2006 – 08/20/2011 \$32,146 (total direct costs)</p>	<p>0%</p>
<p>Phase IV Trial Evaluating Health-Related Quality of Life and Serious Bacterial Infections in Subjects with Primary Immunodeficiency Disorder (PID) Treated with Subcutaneous Immune Globulin Following Conversion From Intravenous Immune Globulin</p>		
<p>Florida Department of Health Sleasman (PI)</p>	<p>09/01/2007 – 09/30/2008</p>	<p>1%</p>
<p>Aquatic Toxins Program</p>	<p>\$36,569</p>	

NIH R21 AI078450-01 Sleasman (PI) 04/01/2008 – 03/31/2010 3%
\$231,375 (annual direct costs)

Characterization of novel polyreactive anti-HIV antibodies in autoimmunity

The long-term goal of this proposed research is to develop strategies that lead to induction of broadly reactive neutralizing antibodies that can prevent infection by a wide variety of clinically relevant strains

Grifols – Protocol Number #IG0705 Sleasman (PI) 08/01/2008 – 07/31/2010 0%

Evaluation of the Efficacy and Safety of FLEBOGAMMA 5% DIF [Immune Globulin Intravenous (Human)] for Replacement Therapy in Pediatric Subjects with Primary Immunodeficiency (PID).

BOOKS, BOOK CHAPTERS AND REVIEWS

1. Barrett DJ, **Sleasman JW**. Immunodeficiency Disorders in Infants and Children. In: *Current Therapy in Infectious Disease* (EH Kass EH, R Platt, eds.), B. C. Decker, Inc., Philadelphia, PA, pp. 51-68, 1990.
2. Barrett DJ, Schatz DA, **Sleasman JW**. Immunoregulatory CD4+ T cell subpopulations: Enumeration, activation and functional analysis in normals and autoimmune disease. In: *Topics in Pediatrics* (H Pomerance, B Bercu, (eds.), Springer-Verlag, NY, pp. 83-95, 1990.
3. **Sleasman JW**, Scott GB. Pediatric HIV Infection: An Update. *J Florida Med Assoc* 78:673-7, 1991.
4. **Sleasman JW**, Goodenow MM. Pathogenesis and natural history of HIV infection. *J Florida Med Assoc* 78:678-81, 1991.
5. Goodenow MM, **Sleasman JW**, Lamers S. Persistence of Multiple Maternal HIV-1 Genotypes in Infants Infected by Perinatal Transmission. In: *Vaccines93*, Cold Spring Harbor Press, pp. 125-129, 1993.
6. **Sleasman JW**, Goodenow MM. HIV 1 Infection: Pathogenesis and Natural History. In: *Clinical Manual on HIV and AIDS*, (JW Shands, DL Seckinger, eds.), Florida Medical Association, Inc., Jacksonville, FL, pp. 1-6, 1995.
7. Scott GB, **Sleasman JW** (eds.). *A Guide for Primary Health Care Providers*, University of Florida Press, Gainesville, FL, 1996. **Sleasman JW**.
8. Diaz LE, **Sleasman JW**. Factors Influencing Mother-Child Transmission of HIV-1. *J Florida Med Assoc* 83: 244-248, 1996.
9. **Sleasman JW**. The association between immunodeficiency and the development of autoimmune disease. *Adv Den Res* 10:57-61, 1996.
10. Barrett DJ, **Sleasman JW**. Pediatric AIDS: ...So now what do we do? *Contemp Pediatr* 14:111-124, 1997.
11. **Sleasman JW**, Goodenow MM. Human Immunodeficiency Virus and Acquired Immune Deficiency (AIDS). In: *Principles of Molecular Medicine*, (L Jamesson, ed.), Humana Press, Inc., Totowa, NJ, pp 293-297, 1998.
12. **Sleasman JW**, Beatriz L. HIV-1 Infection in Children. In: *Current Management In Child Neurology* (B L. Maria, ed.), B.C. Decker, Inc., Hamilton, Ontario, CA, pp 229-233, 1999.
13. Scott GB, **Sleasman JW**. Pediatric HIV Infection. In: *HIV/AIDS Primary Care Guide 1999 Edition*, (Shands JW, and Bentrop, eds.), University of Florida Press, Gainesville, FL, 1999.

14. **Sleasman JW.** Worlds apart: The impact of antiretroviral therapy on the treatment and prevention of pediatric HIV infection. In: *Current Treatment Options in Infectious Diseases*, 2: 109-113, 1999.
15. **Sleasman JW,** Tuttle D, Goodenow MM. HIV Infection and Acquired Immune Deficiency (AIDS): Pathogenesis and Natural History. In: *Clinical Manual on HIV and AIDS* (Shands JW, Seckinger DL, eds.), Florida Medical Association, Inc., Jacksonville, FL, 1999.
16. **Sleasman JW,** Bender B. HIV/AIDS. In: *A Patient-Oriented Problem-Solving (POPS) System* (Online publication, University of Florida, Gainesville, FL), 1999.
17. Goodenow MM, Perez EE, **Sleasman JW.** Protease Inhibitors and HIV-1 Genetic Variability in Infected Children. In: *Human Retroviral Infection: Immunological and Molecular Theories* (H. Friedman, K. Ugen, M. Bendinelli, eds.), Plenum Publishing Corporation, New York, NY, pp.287-305, 2000.
18. Virella G, **Sleasman JW.** Diagnosis of Immunodeficiency Diseases. In: *Medical Immunology* (G Virella, ed.), Marcel Dekker, Inc., New York, NY, pp 555-572, 2001.
19. Virella G, **Sleasman JW.** Primary Immunodeficiency Diseases. In: *Medical Immunology* (G Virella, ed.), Marcel Dekker, Inc., New York, NY, pp 573-599, 2001.
20. **Sleasman, J.W.,** Kahler, D. Antiretroviral Therapy in Children. In: *HIV/AIDS Primary Care Guide 2002 Edition*, University of Florida Press, Gainesville, FL, pp 245-265, 2002.
21. **Sleasman JW,** Goodenow MM. HIV-1 Infection. In: *The Journal of Allergy and Clinical Immunology's Primer on Allergic and Immunologic Diseases* (WT Shearer, JT Li, eds.), 111: S582-S592, 2003.
22. **Sleasman JW.** Tele-Lecture Clinics: Evaluation for Primary Immunodeficiency Disease. *Pediatric Infections Forum V*: 8-9 (Jun) 2003.
23. Goodenow MM, Rose SL, Tuttle DL, **Sleasman JW.** HIV-1 fitness and macrophages. *J Leukoc Biol* 74:657-666, 2003.
24. Saxonhouse MA, **Sleasman JW.** Immunodeficiency disease of the Neonate. In: *Neonatal Hematology.* (P de Alarcon, ed.), Cambridge University Press, Cambridge, United Kingdom, 2005.
25. Farber DL, **Sleasman JW,** Virella G. Immune Response: Antigens, Lymphocytes, and Accessory Cells. In: *Medical Immunology*, 6th Edition (G. Virella, ed.) Informa Healthcare, New York, NY, pp 35-53, 2007.
26. **Sleasman JW,** Virella G. Diagnosis of Immunodeficiency Diseases. In: *Medical Immunology*, 6th Edition (G. Virella, ed.) Informa Healthcare, New York, NY, pp 397-451, 2007.
27. **Sleasman JW,** Virella G. Primary Immunodeficiency Diseases. In: *Medical Immunology*, 6th Edition (G. Virella, ed.) Informa Healthcare, New York, NY, pp 409-428, 2007.
28. **Sleasman JW,** Virella G. AIDS and Other Acquired Immunodeficiency Diseases. In: *Medical Immunology*, 6th Edition (G. Virella, ed.) Informa Healthcare, New York, NY, pp 429-451, 2007.
29. Chinratanapisit S, Sriaroon P, **Sleasman JW.** Diagnostic approach of the adult with suspected immune deficiency. World Allergy Organization website 2008

PEER REVIEWED PUBLICATIONS

1. Garin EH, **Sleasman JW**, Richards GA, Irvani AA, Fennell RS. Pulse methylprednisolone therapy compared to high-dose prednisone in systemic lupus erythematosus (SLE) nephritis. *European Journal of Pediatrics* 45:380-383, 1986.
2. McCrohan M, Huang SW, **Sleasman JW**, Klein PA, Kuo KJ. Plasma thrombospondin: A reliable indicator of intravascular platelet activation. *Thrombosis and Haemostasis* 58:850-852, 1987.
3. Gee AP, Lee C, **Sleasman JW**, Madden M, Ugelstad J, Barrett DJ. T lymphocyte depletion of human peripheral blood and bone marrow using monoclonal antibodies and magnetic microspheres. *Bone Marrow Transplantation* 2:155-163, 1987.
4. **Sleasman JW**, Tedder TF, Barrett DJ. Combined Immunodeficiency due to the selective absence of CD4 inducer T lymphocytes. *Clinical Immunology and Immunopathology* 55:401-417, 1990.
5. **Sleasman JW**, Morimoto C, Schlossman SF, Tedder TF. The role of functionally distinct helper T lymphocyte subpopulations in the induction of human B cell differentiation. *European Journal of Immunology* 20:1357-66, 1990.
6. **Sleasman JW**, Henderson M, Barrett DJ. Con A-induced suppressor cell function depends on the activation of the CD4⁺ CD45RA induced T cell subpopulation. *Cell Immunol* 133:367-78, 1991.
7. Schatz DA, Lang F, Cantor AB, Riley WJ, Maclaren NK, **Sleasman JW**, Barrett DJ. CD5+ B lymphocytes in high risk islet cell antibody positive and newly-diagnosed insulin dependent diabetic subjects. *Diabetes* 40:1314-1318, 1991.
8. Matsuyama T, Yamada A, Deusch K, **Sleasman JW**, Daley JF, Torimoto Y, Abe T. Cytochalasins enhance the proliferation of CD4 cells through the CD3-Ti antigen receptor complex or the CD2 molecule through an effect on early events of activation. *Journal of Immunology* 146:3736-41, 1991.
9. Barrett DJ, **Sleasman JW**, Schatz DA, Steinitz M. Human Anti-pneumococcal Polysaccharide Antibodies are secreted by the CD5+ B Cell Lineage. *Cellular Immunology* 143: 66-79, 1992.
10. **Sleasman JW**, Hemenway C, Klein AS, Barrett DJ. Corticosteroids Improve Survival of Children with AIDS and Pneumocystis carinii Pneumonia. *American Journal of Diseases of Children*, 147:30-34, 1993.
11. Lamers SL, **Sleasman JW**, She JX, Barrie KA, Pomeroy SM, Barrett DJ, Goodenow MM. Independent Variation and Positive Selection in *env* V1 and V2 Domains within Maternal-Infant Strains of Human Immunodeficiency Virus Type-1 in Vivo. *Journal of Virology* 67:3951-60, 1993.
12. Friedman SM, Mames RN, **Sleasman JW**, Whitcup SM. Acute Retinal Necrosis after Chickenpox in a Patient with Acquired Immunodeficiency Syndrome. *Archives of Ophthalmology* 111:1607-8, 1993.
13. Lamers S, **Sleasman JW**, Barrie K, Pomeroy S., Barrett DJ, Goodenow MM. Persistence of Multiple Maternal Genotypes of Human Immunodeficiency Virus Type 1 in Infants Infected by Perinatal Transmission. *Journal of Clinical Investigation* 93:380-90, 1994.
14. **Sleasman JW**, Harville TO, White GB, George JF, Barrett DJ, Goodenow MM. Arrested Rearrangement of T Cell Receptor V β Genes in Thymocytes from Children with X-linked Severe Combined Immunodeficiency Disease. *Journal of Immunology* 153:442-448, 1994.
15. Tolaymat A, Al-Mousily F, **Sleasman JW**, Paryani S, Neiberger R. Hyponatremia in Pediatric Patients with HIV-1 Infection. *Southern Medical Journal* J 88:1039-1042, 1995.

16. Aleixo LF, Goodenow MM, Sleasman **JW**. Molecular Analysis of Highly Enriched Populations of T-cell-depleted Monocytes. *Clinical and Diagnostic Laboratory Immunology* 2:733-739, 1995.
17. Barrie KA, Perez EE, Lamers SL, Farmerie WG, Dunn BM, **Sleasman JW**, Goodenow MM. Natural variation in HIV-1 protease, gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: Amino acid substitutions in the absence of protease inhibitors in mothers and children infected by Human Immunodeficiency Virus Type 1. *Virology* 219:407-416, 1996.
18. Lamers SL, **Sleasman JW**, Goodenow MM. A model for alignment of *env* V1 and V2 hypervariable domains from human and simian immunodeficiency viruses. *AIDS Research and Human Retroviruses* 12:1169-1178. 1996.
19. Rasmussen SA, Williams CA, Ayoub EM, **Sleasman JW**, Gray BA, Bent-Williams A, Stalker HJ, Zori RT. Juvenile Rheumatoid Arthritis in Velo-Cardio-Facial Syndrome: Coincidence or Unusual Complication? *American Journal of Medical Genetics* 64:546-550. 1996.
20. **Sleasman JW**, Aleixo LF, Morton A, Skoda-Smith S, Goodenow MM. CD4+ memory T cells are the predominant HIV-1 infected lymphocyte population in neonates and children. *AIDS*. 10:1477-1484, 1996.
21. Slayton W, Anstine D, Lakhdar F, **Sleasman JW**, Neiberger R. Tetany in a child with AIDS receiving intravenous tobramycin. *Southern Medical Journal* 89:1108-1110. 1996.
22. Massengill S, Hedrick C, Ayoub EM, **Sleasman JW**, Kao KJ. Antiphospholipid antibodies in pediatric lupus nephritis. *American Journal of Kidney Diseases* 29:355-361, 1996.
23. Roig JC, McMurray CA, **Sleasman JW**, Neu J. T-lymphocyte subsets and natural killer cells in very low birth weight infants. *Journal of Nutrition* 126:1115S-1120S, 1996.
24. Aleixo LF, Goodenow MM, **Sleasman JW**. Zidovudine administered to HIV-1 infected women and their neonates reduces pediatric infection independent of an effect on levels of maternal virus. *Journal of Pediatrics* 130:906-914, 1997.
25. Roig JC, Auestad N, Veerman M, Bowling D, McMurray C, Knight T, **Sleasman JW**, Neu N. Enteral Supplementation of Glutamine in the Very Low Birth Weight Infant: Effect on Cellular Immune Function. *Infant Nutritional Digest* 4:16-18, 1997.
26. Kontny HU, **Sleasman JW**, Kingma DW, Jaffe ES, Avila N, Pizzo PA, Mueller BU. Multilocular thymic cysts in children with human immunodeficiency virus infection: Clinical and pathological aspects. *Journal of Pediatrics* 131: 264-270, 1997.
27. **Sleasman JW**, Leon BH, Alexio LF, Rojas M, Goodenow MM. Immunomagnetic Selection of Purified Monocyte and Lymphocyte Populations from Peripheral Blood Mononuclear Cells following Cryopreservation. *Clinic and Diagnostic Laboratory Immunology* 4:653-658, 1997.
28. Neu J, Roig JC, Meetze WH, Veerman M, Carter C, Millsaps M, Bowling D, Dallas MJ, **Sleasman JW**, Knight T, Auestad N. Enteral Glutamine Supplementation for Very Low Birth Weight Infants Decreases Morbidity. *Journal of Pediatrics* 131:691-699, 1997.
29. Massengill SF, Goodenow MM, **Sleasman JW**. SLE Nephritis is associated with an oligoclonal expansion of intrarenal T cells. *American Journal of Kidney Diseases* 31:418-426, 1998.
30. Mueller BU, Nelson RP, Jr., **Sleasman JW**, Zuckerman J, Heath-Chiozzi M, Steinberg SM, Balis FM, Brouwers P, Hsu A, Saulis R, Sei S, Wood LV, Zeichner S, Pizzuti D, Pizzo, and the Ritonavir Protocol Working Group of the HIV and AIDS Malignancy Branch, National Cancer Institute. A Phase I/II study of the protease inhibitor Ritonavir in children with HIV infection. *Pediatrics* 101:335-343, 1998.

31. Machado LS, **Sleasman JW**, Ford MJ. Bacillus Species Infection of the Skin as a Presentation of Severe Combined Immunodeficiency Disease. *Journal of American Academy of Dermatology* 39:285-287, 1998.
32. Tuttle DL, Harrison JK, Anders C, **Sleasman JW**, Goodenow MM. Expression of CCR5 Increases during Monocyte Differentiation and Directly Mediates Macrophage Susceptibility to Infection by Human Immunodeficiency Virus Type 1. *Journal of Virology* 72: 4062-4969, 1998.
33. Mueller BU, **Sleasman JW**, Nelson RP, Jr., Smith S, Deutsch PJ, Ju W, Steinberg SM, Balis FM, Jarosinski PF, Brouwers P, Mistry G, Winchell G, Zwierski S, Boss C, Jankelevich S, Sei S, Wood LV, Zeichner S, Pizzo PA: A Phase/II study of the protease inhibitor indinavir in children with HIV infection. *Pediatrics*.102:101-109, 1998.
34. **Sleasman JW**, Nelson RP, Jr., Goodenow MM, Wilfret D, Hutson A, Heath-Chiozzi M, Baseler M, Zuckerman J, Pizzo PA, Mueller BU. Immunoreconstitution following ritonavir therapy in HIV-infected children involves multiple lymphocyte lineages. *Journal of Pediatrics* 134: 597-606, 1999.
35. Burkhardt B, Coberley C, **Sleasman JW**, Goodenow MM, Kephart D. Molecular Diagnostics: Postmortem isolation and analysis of human genomic DNA from HIV-infected tissues. *Promega Notes* 71:16-17, 1999.
36. Zeichner S, Palumbo P, Feng Y, Xiao X, Gee D, **Sleasman JW**, Goodenow MM, Biggar R, Dimitrov D. Rapid Telomere Shortening in Children *Blood* 93:1-8, 1999.
37. McIntosh S, Cooper E, Xu J, Mirochnick M, Lindsey J, Jacobus D, Mofenson L, Yogev R, Spector SA, Sullivan JL, Sacks H, Kovacks A, Nachman S, **Sleasman JW**, Bonaguara V, McNamara J, and Members of the ACTG 179 Study Team. Toxicity and efficacy of daily vs. weekly dapsone for prevention of Pneumocystis carinii pneumonia in children infected with human immunodeficiency virus. AIDS Clinical Trials Group. *Pediatric Infectious Disease Journal* 18:432-9, 1999.
38. Aquino de Jesus MJ, Anders C, Miller G, **Sleasman JW**, Goodenow MM, Andiman WA. Genetically and epidemiologically-related "non-syncytium-inducing" isolates of HIV-1 display heterogeneous growth patterns in macrophages. *Journal of Medical Virology* 61:171-180, 2000.
39. Kou ZC, Puhr JS, Rojas M, McCormick W, Goodenow MM, **Sleasman JW**. T Cell Receptor V β Repertoire CDR 3 Length Diversity Differs Within CD45RA and CD45RO T Cell Subsets in Healthy and HIV-infected Children. Associate editor, *Clinical and Diagnostic Laboratory Immunology* 7: 953-959, 2000.
40. Briggs DR, Tuttle DL, **Sleasman JW**, Goodenow MM. Envelope V3 Amino Acid Sequence Predicts HIV-1 Phenotype (Coreceptor Usage and Tropism for Macrophages). *AIDS* 14: , 2937 – 2939, 2000.
41. Saez-Llorens X, Nelson RP, Jr., Emmanuel P, Wixnia A, Mitchell C, Church J, **Sleasman JW**, Van Dyke R, Richardson CG, Cutrell A, Spreen W, Hetherington S, and the CNAA 3006 Study Team; A Randomized, Double-Blind Study of Triple Nucleoside Therapy of Abacavir, Lamivudine, and Zidovudine versus Lamivudine in Previously Treated HIV-1-Infected Children. *Pediatrics*. 107: E4, 2001.
42. Perez EP, Rose LS, Peyser B, Burkhardt BR, Lamers SL, Pascual C, Dunn BM, Mueller BU, Hutson AD, **Sleasman JW**, Goodenow MM. HIV-1 protease predicts immune and viral response to combination therapy with protease inhibitors (PI) in PI-naïve children. *Journal of Infectious Diseases* 183: 579-588, 2001.
43. Jankelevich S, Mueller BU, Mackall CL, Smith S, Zwierski S, Wood LV, Zeichner SL, Serchuck L,

Steinberg SM, Nelson RP, Jr., **Sleasman JW**, Nguyen BY, Pizzo PA, Yarchoan R. Long-term Virologic and Immunologic Responses in Human Immunodeficiency Virus Type 1-Infected Children Treated with Indinavir, Zidovudine, and Lamivudine. *Journal of Infectious Diseases* 183:1116-1120, 2001.

44. Kimberlin DW, Lin CY, Jacobs RF, Powell DA, Corey L, Gruber W, Rathore M, Bradley J, Diaz P, Kumar M, Arvin AM, Gutierrez K, Shelton M, Weiner LB, **Sleasman JW**, Sierra T, Weller S, Soong SJ, Lakeman FD, Whitely RJ, and the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. The Safety and Efficacy of High-Dose Acyclovir in the Management of Neonatal herpes Simplex Virus Infections. *Pediatrics* 108:230-238, 2001.
45. Kimberlin DW, Lin C-Y, Jacobs RF, Powell DA, Frenkel L, Gruber W, Rathore M, Bradley J, Diaz PS, Kumar M, Arvin AM, Gutierrez K, Shelton M, Weiner L.B, **Sleasman JW**, Sierra T, Soong S-J, Lakeman FD, Whitely RJ, and the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. The Natural History of Neonatal Herpes Simplex Virus Infections in the Acyclovir Era. *Pediatrics* 108:223-229, 2001.
46. Ghaffari G, Passalacqua DJ, Bender BS, Briggs DJ, Goodenow MM, **Sleasman JW**. Human Lymphocyte Proliferation Responses Following Primary Immunization Using Rabies Vaccine as a Neoantigen. *Clinical and Diagnostic Laboratory Immunology* 8:880-883, 2001.
47. Goodenow MM, Bloom G, Rose SL, Pomeroy S.M, O'Brien RO, Perez EE, **Sleasman JW**, Dunn BM. Naturally Occurring Amino Acid Polymorphisms in Human Immunodeficiency Virus Type 1 (HIV-1) Gag p7^{NC} and the C-Cleavage Site Impact Gag-Pol Processing by HIV-1 Protease. *Virology* 292: 137-149, 2002.
48. Tuttle DL, Anders CB, Aquino-de Jesus MJ, Poole P, Lamers SL, Briggs DR, Pomeroy SM, Alexander L., Peden KWC, Andiman WA, **Sleasman JW**, Goodenow MM. Increased Replication by Nonsyncytium- Inducing HIV-1 Isolates in Monocyte-Derived Macrophages is Linked to Advanced Disease in Infected Children. *AIDS Research and Human Retroviruses* 18:353-362, 2002.
49. Aranda JM Jr., Scornik JC, Normann SJ, Lottenberg R, Schofield RS, Pauly DF, Miles M, Hill JA, **Sleasman JW**, Skoda-Smith S. Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac vascular rejection: a case report. *Transplantation* 73: 907-910, 2002.
50. Kou ZC, Puhr JS, Wu SS, Goodenow MM, **Sleasman JW**. Combination Antiretroviral Therapy Results in a Rapid Increase in T Cell Receptor Variable Region β Repertoire Diversity within CD45RA CD8 T Cells in Human Immunodeficiency Virus-Infected Children. *Journal of Infectious Diseases* 187:385-397, 2003.
51. Kohler JJ, Tuttle DL, Coberley CR, **Sleasman JW**, Goodenow MM. Human Immunodeficiency Virus Type 1 (HIV-1) Induces Activation of Multiple STATs in CD4⁺ Cells of Lymphocyte and Monocyte/Macrophage Lineages. *Journal of Leukocyte Biology* 73:407-416, 2003.
52. Litherland SA, She J-X, Schatz D, Fuller K, Hutson AD, Peng RH, Li Y, Grebe KM, Whittaker DS, Bahjat K, Hopkins D, Fang Q, Spies PD, North K, Wasserfall C, Cook R, Dennis MA, Crockett S, **Sleasman JW**, Kocher J, Muir A, Silverstein J, Atkinson M, Clare-Salzler MJ. Aberrant Monocyte Prostaglandin Synthase 2 (PGS2) Expression in Type 1 Diabetes Before and After Disease Onset. *Pediatric Diabetes* 4:10-18, 2003.
53. Tuttle DL, Coberley CR, Xie X, Kou ZC, **Sleasman JW**, Goodenow MM. Effects of Human Immunodeficiency Virus Type 1 Infection on CCR5 and CXCR4 Coreceptor Expression on CD4 T Lymphocyte Subsets in Infants and Adolescents. *AIDS Research and Human Retroviruses* 20:305-313, 2004.
54. Tangsinmankong N, Kamchaisatian W, Lujan-Zilbermann J, Brown CL, **Sleasman JW**, Emmanuel PJ.

- Varicella Zoster as a Manifestation of Immune Restoration Disease in HIV-Infected Children. *Journal of Allergy and Clinical Immunology* 113:742-746, 2004.
55. Tangsinmankong N, Kamchaisatian W, Day NK, **Sleasman JW**, Emmanuel PJ. Immunogenicity of 23-Valent Pneumococcal Polysaccharide Vaccine in HIV-1 Infected Children on Highly Active Antiretroviral Therapy (HAART). *Annals of Allergy, Asthma, and Immunology* 92:558-564, 2004.
 56. Marhefka SL, Farley JJ, Rodriguez JR, Sandrik LL, **Sleasman JW**, Tepper VJ. Clinical assessment of medication adherence among HIV-infected children: examination of the Treatment Interview Protocol (TIP). *AIDS Care* 16:323-338, 2004.
 57. Coberley CR, Kohler JJ, Brown JN, Oshier JT, Baker HV, Popp MM, **Sleasman JW**, Goodenow MM. Impact on Genetic Networks in Human Macrophages by a CCR5-Strain of Human Immunodeficiency Virus Type-1 (HIV-1). *Journal of Virology* 78:11477-1486, 2004.
 58. Rucker P, Day NK, Good RA, Kamchaisatian W, Emmanuel P, **Sleasman JW**, Mayeski C, Dinglasan E, Haraguchi S, Tangsinmankong N. Effect of Influenza Virus on the Expression of Human Immunodeficiency Virus Co-Receptor CCR5. *Annals of Allergy, Asthma, and Immunology* 93: 272-276, 2004.
 59. Ghaffari G, Passalacqua DJ, Caicedo JL, Goodenow MM, **Sleasman JW**. Two-year clinical and immune outcomes in HIV-infected children who reconstitute CD4 T cells without control of viral replication following combination antiretroviral therapy. *Pediatrics* 114:604-611, 2004.
 60. Uphold CR, Maruenda J, Yarandi HN, **Sleasman JW**, Bender BS. HIV and Older Adults: Clinical outcomes in the era of HAART. *Journal of Gerontology Nursing* 7:16-24; 2004.
 61. Ghaffari G, Tuttle DL, Briggs D, Burkhardt BR, Bhatt D, Andiman WA, **Sleasman JW**, Goodenow MM. Complex determinants in human immunodeficiency virus type 1 (HIV-1) envelope gp120 mediate CXCR4-dependent infection of macrophages. *Journal of Virology* 79:13250-13261, 2005.
 62. Martin DP, Tangsinmankong N, **Sleasman JW**, Day-Good NK, Wongchantara DR. Acrodermatitis enteropathica-like eruption and food allergy. *Annals of Allergy, Asthma, and Immunology* 93:398-401, 2005.
 63. Haraguchi S, Day NK, Kamchaisatian W, Beigier-Pompadre M, Stenger S, Tangsinmankong N, **Sleasman JW**, Pizzo SV, Cianciolo G. LMP-420, a small molecule inhibitor of TNF-alpha, reduces replication of HIV-1 and Mycobacterium tuberculosis in human cells. *AIDS Research and Therapy* 3:8, 2006.
 64. Lavi RF, Kamchaisatian W, **Sleasman JW**, Martin DP, Haraguchi S, Day NK, Tangsinmankong N. Thymic output markers indicate immune dysfunction in DiGeorge syndrome. *Journal of Allergy and Clinical Immunology* [Letters to the Editor] Nov;118(5):1184-6. Epub 2006 Sep 25.
 65. Kamchaisatian W, Wanwatsuntikul W, Sleasman JW, Tangsinmankong N. Validation of current Joint American Academy of Allergy, Asthma & Immunology and American College of Allergy, Asthma and Immunology guidelines for antibody response to the 23-valent pneumococcal vaccine using a population of HIV-infected children. *Journal of Allergy and Clinical Immunology* 2006 Dec; 118 (6):1336-41.
 66. Pahwa S, Muresan P, **Sleasman JW**, Fenton T, Moye J, Deveikis A, Wara D, Van Dyke R and the PACTG-402 team: Phase I/II trial of intermittent subcutaneous interleukin-2 administration in pediatric patients with moderate immune suppression: Results of pediatric AIDS clinical trials study 402. *Journal*

of Allergy and Clinical Immunology [Letters to the Editor] 119:1538-1541, 2007 [Epub 2007].

67. Rodriguez CA, Koch S, Goodenow MM, **Sleasman JW**. Clinical implications of discordant viral and immune outcomes following protease inhibitor containing antiretroviral therapy for HIV-infected children. *Immunology Research* DOI 10.1007/s12026-007-0031-1, 2007.
68. Sanka M, Tangsinmankong N, Loscalzo M, **Sleasman JW**, Dorsey MJ. Complete DiGeorge syndrome associated with CHD7 mutation. *Journal of Allergy and Clinical Immunology* [Letters to the Editor] 120:952-954, 2007
69. Salemi M, Brukhardt BR, Pomeroy St, Lowe A, Ghaffari G, **Sleasman JW**, Goodenow MM. Episodic selection drives the evolution/amplification of CXCR4-using HIV-1 quasispecies in thymus from children. PLoS ONE 2 (9): e950. doi: 10.1016/journal.pone.0000950, 2007.
70. Yin L, Rodriguez CA, Hou W, Potter O, Caplan MR, Goodenow MM, **Sleasman JW**. Antiretroviral therapy corrects HIV-1-induced expansion of CD8⁺ CD45RA CD27-CD11^{bright} activated T cells. *Journal of Allergy and Clinical Immunology* 122: 166-172, doi: 10.1016, 2008
71. Brown JN, Kohler JJ, Coberley CR, **Sleasman JW**, Goodenow MM. HIV-1 Activates Macrophages Independent of Toll-like Receptors, PLoS One 3(12): e3664, 2008.
72. Ho SK, Coman RM, Bunger JC, Rose SL, O'Brien P, Munoz I, Dunn BM, **Sleasman JW**, Goodenow MM. Drug-associated changes in amino acid residues in Gag p2, p7NC, and p6Gag/p6Pol in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response. *Virology* 378: 272-281 epub 2008.
73. Church JA, Borte M, Taki H, Nelson RP, **Sleasman JW**, Knutsen AP, Le Gall E, Debre M, Bichler J. Efficacy and safety of privigen in children and adolescents with primary immunodeficiency. *Pediatr Allergy Immunol* 2008
74. Walsh CJ, Leggett SR, Strohbehn K, Pierce RH, **Sleasman JW**. Effects of in vitro Brevetoxin Exposure on Apoptosis and cellular Metabolism in a Leukemic T Cell Line (Jurkat) *J Allergy Clin Immunol* 2008; 122: 166-72.
75. **Sleasman JW**, Robbins B, Cross S, Lindsey J, Kraimer J, Heckman B, Sprenger HL, Tustin N, Pakes GE, Capparelli E. Abacavir pharmacokinetics during chronic therapy in HIV-1 infected adolescents and young adults. *Clin Pharmacol Ther.* 2009 Apr; 85(4):394-401. epub 2008 Dec 31.
76. Dorsey M, Petrovic A, Morrow M, Lindsey J, Dishaw L, **Sleasman J**. FOXP3 expression following bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning. *Immunol Res* 2009 May; 44 (1-3):179-84.
77. Wasserman, R, Church, J, Peter, H, **Sleasman, JW**, Melamed, I, Stein, M, Bichler, J Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency. *EUFEPS* 2009 June; 37 (4):272-278.
78. Ho SK, Perez EE, Rose SL, Coman R, Lowe AC, Hou W, Ma C, Lawrence RM, Dunn BM, **Sleasman JW**, Goodenow MM. Genetic determinants in HIV-1 Gag and Env V3 are related to viral response to combination antiretroviral therapy with a protease inhibitor. 2009 August *AIDS*. 23(13):1631-1640,

PUBLICATIONS SUBMITTED

1. Nelson R, McKinney RE, Fenton T, Spector S, Nguyen B, and **Sleasman JW**, PACTG 395 and MK 068 Protocol Teams. Safety, pharmacokinetics, and efficacy of indinavir in combination with stavudine and lamivudine in children with HIV-1 infection.
2. Siri DD, **Sleasman JW**, Tangsinmankong N. Natural killer cell impairment in a patient with pachyonychia congenita.
3. Ho SK, Morrow M, Coman RM, Rose SL, **Sleasman JW**, Goodenow MM. P-glycoprotein activity contributes to differences in sensitivity to HIV-1 protease inhibitors between viruses that replicate in CCR5 or CXCR4 subsets of CD4 T lymphocytes.
4. Yin LI, Zhong K, Rodriguez CA, Hou W, Goodenow MM, **Sleasman JW**. Antiretroviral Therapy Restores Diversity in the T cell receptor V β Repertoire of CD4 T cell Subpopulations among HIV-1 Infected Children and Adolescents.
5. **Sleasman JW**, Duff, C, Dunaway, T, Rojavin, M, Stein, M. Tolerability of a new 10% liquid immunoglobulin for intravenous use, Privigen® at different infusion rates.

ABSTRACTS

1. **Sleasman JW**, Stapleton FB, Tonkin I. Marked uricosuric effect of contrast media during cardiac catheterization in children. *SPR Pediatr Res* 17:123A, 1982.
2. **Sleasman JW**, Stapleton FB, Tonkin I. The effect of contrast media on renal function in children undergoing cardiac catheterization. *SSPR Clin Res* 30:5, 1982.
3. **Sleasman JW**, Garin E. Effect of methylprednisolone pulse therapy on serum C₃ and C4 complement components and anti double-stranded deoxyribonucleic acid antibody in patients with lupus nephritis. American Academy of Pediatrics Section on Nephrology, Chicago, IL, September, 1984.
4. Barrett DJ, **Sleasman JW**, Lee C, Gross S, Ugelstad J, Gee AP. T Lymphocyte depletion of bone marrow using monoclonal antibodies and magnetic microspheres. *Pediatr Res* 20:292A (Apr) 1986.
5. **Sleasman JW**, Barrett DJ. Combined immunodeficiency due to congenital absence of T4 helper lymphocytes. *Pediatr Res* 20:300A (Apr) 1986.
6. Gee AP, Lee C, Sleasman **JW**, Madden M, Ugelstad J, Barrett DJ. T lymphocyte depletion using magnetic microspheres and monoclonal antibodies. *Clin Res* 34:246A (Feb) 1986.
7. Gee AP, Lee C, Bruce K, **Sleasman JW**, Janssen W, Bauer P, Grahampole J, Gross S, Barrett DJ. Magnetic depletion of subpopulations of cells from bone marrow that is to be used for transplantation. American Cancer Society, Florida Chapter, 1986.
8. **Sleasman JW**, Henderson M, Barrett DJ. Concanavalin A activates the suppressor/inducer subpopulation of CD4 T lymphocytes. *SPR Pediatr Res* 21:318A, 1987.
9. ***Sleasman JW**, Henderson M, Barrett DJ. Activation of suppressor/inducer subpopulation of CD4 lymphocytes with concanavalin A. *SSPR Clin Res* 35:1, 1987.
10. **Sleasman JW**, Barrett DJ. Ontogeny of human CD4 lymphocyte subpopulations following bone marrow

transplantation. *Pediatr Res* 21:318A, 1987.

11. **Sleasman JW**, Penta A, Schlossman SF, Tedder TF. Phosphorylation of the B1 (CD20) molecule by normal and malignant human B lymphocytes. 72nd Annual Meeting of American Societies of Experimental Biology FASEB J 2:6790, 1988.
12. ***Sleasman JW**, Morimoto C, Schlossman SF, Tedder TF. The role of functionally distinct helper T lymphocyte subpopulations in the induction of B cell differentiation 73rd Annual Meeting of American Societies of Experimental Biology. FASEB J 3:3353, 1989.
13. ***Sleasman JW**, Schatz DA, Barrett DJ. Abnormal expression of immature B cell markers in humoral immunodeficiencies. *SPR* May 1989.
14. ***Sleasman JW**, Barrett DJ, Tedder TF. B cell differentiation requires direct T-B cell interactions. 7th International Congress of Immunology, West Berlin, Germany, August 1989.
15. ***Sleasman JW**, Morimoto C, Schlossman SF, Tedder TF. The role of functionally distinct helper T lymphocyte subpopulations in the induction of B cell differentiation. 7th International Congress of Immunology, West Berlin, Germany, August 1989.
16. ***Sleasman JW**, Schatz DA, Harville TO, Barrett DJ. CD5+ B lymphocytes decrease during childhood but are normal in polysaccharide vaccine non-responders. *SPR* May, 1990.
17. Barrett DJ, **Sleasman JW**. Human B cells secreting antibody to pneumococcal polysaccharide are large recirculating cells which bear the phenotype CD20+ PCA1+ HB7- HB4-FMC7-and CD5-.*SPR*, May, 1990.
18. *Schatz DA, Riley WJ, **Sleasman JW**, Dush P, Barrett DJ. Increased CD5+ B lymphocytes in "pre-diabetic" and newly diagnosed diabetic subjects. *SPR* May, 1990.
19. Barrett DJ, **Sleasman JW**. Human pneumococcal polysaccharide antibody secretion is derived from the CD5⁻ late-maturing B cell subpopulation. Clinical Immunology Society Meeting November 1990.
20. Lamers S, **Sleasman JW**, Barrett DJ, Goodenow MM. Genetic variability in HIV-1 in individuals infected with related viruses. *J Acquir Immune Defic Syndr*, 4:109, 1991.
21. *HarvilleTO, **Sleasman JW**, Goodenow MG, Barrett DJ. T cell receptor gene recombinants identified in combined immunodeficiency disease. *Pediatric Res* 29:157A, (Apr) 1991.
22. ***Sleasman JW**, Holmes PD, Barrett DJ. Pokeweed nitrogen (PWM) enhances formation of T cell-to-B cell cellular conjugates. *Pediatr Res* 29:163A, (Apr) 1991.
23. **Sleasman JW**, De Severino A, Schatz D, Barrett DJ. HIV infected children with lymphoid interstitial pneumonitis (LIP) express low numbers of CD5⁺ B cells. *Pediatr Res* 29.163A, (Apr) 1991.
24. *Harville TO, **Sleasman JW**, Goodenow MG, Barrett DJ. T cell receptor gene recombinants identified in combined immunodeficiency disease. *Pediatr Res* 29:157, (May) 1991.
25. Fontenot EE, **Sleasman JW**, Staples ED, Selman S, McGinn C, Epstein ML. Complications from long-term steroid therapy in pediatric cardiac transplant patients are rare. American Heart Association. 64th Scientific Sessions.
26. ***Sleasman JW**, Barrett DJ. Abnormal expression of immature B cell markers in humoral immunodeficiencies. *Clin Res* 1991.

27. Barrett DJ, Harville TO, **Sleasman JW**, Goodenow M. Does the human pneumococcal antibody response show restricted Ig V_H gene utilization. Clin Res 39:821A, (Dec) 1991.
28. *Goodenow MM, **Sleasman JW**, Lamers S, Barrie K, Barrett DJ. HIV-1 displays greater genetic variability over time in infants than their infected mothers. Clin Res 39:862A, (Dec) 1991.
29. ***Sleasman JW**, Hemenway C, Klein AS, Barrett DJ. Adjuvant corticosteroid therapy improves the survival of severe pneumocystis carinii pneumonia (PCP) in children with AIDS. Clin Res (Dec) 1991.
30. ***Sleasman JW**, Barrett DJ. Human "Memory" (CD45RO) CD4+ T cells are able to preferentially form cognate cellular interactions with antigen presenting cells. Clin Res 1991.
31. Fontenot EE, **Sleasman JW**, Epstein ML. Complications from long-term steroid therapy in pediatric cardiac transplant patients is rare. American College of Cardiology 41st Annual Scientific Session, April 1992, Dallas, TX, 29:163 (Apr) 1992.
32. Klein AS, Hemenway C, **Sleasman JW**, Barrett DJ. Methylprednisolone decreases mortality in children with HIV and Pneumocystis carinii. 1st World Congress of Pediatric Intensive Care 1992.
33. ***Sleasman JW**, Schatz D, Barrett DJ. Abnormal expression of immature B cell markers in Humoral immunodeficiencies. Pediatr Res 33:29, 1992.
34. *Goodenow MM, **Sleasman JW**, Lamers S, Barrie K, Barrett DJ. HIV-1 displays greater genetic variability over time in infants than their infected mothers. Clin Res 39:862A 1992.
35. *Barrett DJ, Goodenow MM, Harville TO, **Sleasman JW**, White GB. IgH chain usage in human Ab to pneumococcal polysaccharide. Clin Res 39:821A 1992.
36. *Harville TO, **Sleasman JW**, Goodenow MM. Limited utilization of V β gene segments in the T cell receptor from children with X-linked SCID. Pediatr Res 32:101, 1992.
37. ***Sleasman JW**, Barrett DJ. Human "Memory" (CD45RO) CD4+ T cells are able to preferentially form cognate cellular interactions with B cells. Clin Res 1992.
38. *Goodenow MM, Lamers SL, **Sleasman JW**. Independent Variation in env V1-V2 Hypervariable Domains within Maternal-Infant Strains of HIV-1 in vivo. NIH Vaccine R&D, JV1 1391-92 (Sept) 1992.
39. *Goodenow MM, **Sleasman JW**, Lamers S.L. Positive Selection in vivo for Independent Genetic Variation in Maternal-Infant Strains of HIV-1. Clin Res 40:848A, (Dec) 1992.
40. *Goodenow MM, **Sleasman JW**, Lamers SL. Multiple Maternal Genotypes of HIV-1 are transmitted to Infants by Perinatal Infection. Keystone Symposia, Frontiers in HIV Pathogenesis, 29 Mon - 4 Apr '93, Keystone, CO. J Cell Biochem S17E QZ102.
41. *Goodenow MM, **Sleasman JW**, Lamers SL, Barrett DJ. Multiple Maternal HIV-1 Genotypes in Infants Infected by Perinatal Transmission. Clin Res 33:993A, (May) 1993.
42. *Massengill SF, **Sleasman JW**, Goodenow MM. Restricted Heterogeneity of T cell Receptor in SLE Nephritis. Pediatr Res, 33:918A, (May) 1993.
43. *Skoda-Smith S, Morton A, Andrew D, Goodenow MM, **Sleasman JW**. HIV-1 Infection of CD4 Positive T-cell Subpopulations in Infants and Children. Pediatr Res 33:993A, (May) 1993.
44. ***Sleasman JW**, Goodenow MM, White GB, Barrett DJ. T cell Receptor (TCR) Gene Rearrangements are Absent in the Thymic Tissues of Children with X-linked SCID. J Immunol 150:163A, 1993.

45. Goodenow MM, **Sleasman JW**, Lamers SL, Barrett DJ. Perinatal Transmission Involves Multiple Maternal HIV-1 Genotypes. Sixth International Conference on AIDS 6:273, 7 - 11 June '93, Berlin, Germany.
46. Massengill SF, **Sleasman JW**, Goodenow MM. Restricted T cell Receptor V β Gene Utilization in SLE Nephritis. *J Am Soc Nephrol* 4:3:618 (67P), 1993.
47. ***Sleasman JW**, Hutcheson CE, Weiner RS, Miller AM. Successful Bone Marrow Transplantation of Children with X-linked Severe Combined Immunodeficiency Using Bone Marrow Depleted of T Cells by Centrifugal Elutriation. *J Cell Biochem* 18B:G211:72, 1994.
48. ***Sleasman JW**, Goodenow MM. HIV-1 Infection in Peripheral Blood Monocytes and T cell Subsets of Neonates and Infants Infected by Maternal Transmission. *J Cell Biochem* 18B:J122:122, 1994.
49. Al-Mousily F, Tolaymar A, **Sleasman J**, Paryani S, Neiberger R. Hyponatremia in Pediatric Patients with HIV-1 Infection. *Clin Res* 41:4:815A, 1994.
50. Cumming WA, **Sleasman JW**. Massive Thymic Enlargement in Children with Congenital HIV Infection. The Canadian Association of Radiologists, Montreal, Quebec, Canada, January 31, 1995.
51. ***Sleasman JW**, Alexio LF, Goodenow MM. High Levels of HIV-1 Provirus are present in the Monocytes of Infected Neonates. *J Investig Med* 43:1:66A, 1995.
52. Lamers SL, **Sleasman JW**, Goodenow MM. Sequence Alignment Strategy for HIV-1 *env* V1 and V2 Hypervariable Domains. Second National conference on Human Retroviruses and Related Infections, January 29 - February 2, 1995, Washington, D.C.
53. Alexio LF, Goodenow MM, **Sleasman JW**. HIV-1 Infection of Peripheral Blood Monocytes in Neonates. 2nd National Conference on Human Retroviruses and Related Infections, January 29 - February 2, 1995, Washington, D.C.
54. ***Sleasman JW**, Morton A, Skoda-Smith S, Goodenow MM. CD4⁺ Memory T Cells are the Predominant HIV-1 Infected Lymphocyte Population in Neonates and Children. *Pediatr Res* 37:10A:47, 1995.
55. *Ryan-Poirier K, Goodenow MM, Kao KJ, **Sleasman JW**. Antiphospholipid Antibody (aPL) in Children with Human Immunodeficiency Virus (HIV) Infection. *Pediatr Res* 37:187A:1108, 1995.
56. Roig JC, Bowling D, Dallas M, **Sleasman, JW**, Auestad N. Enteral Glutamine Supplementation Decreases Nosocomial Infection and Alters T cell Subset in the Very Low Birth Weight (VLBW) (<1250 Gram) Neonate. *Pediatr Res* 37:285A:1693.1995.
57. *Massengill SF, Ayoub EM, **Sleasman JW**. Intravenous Cyclophosphamide (IVCTX) Therapy in Systemic Lupus Erythematosus (SLE) Nephritis. *Pediatr Res*, 37:366A:2178, 1995.
58. *Massengill SF, **Sleasman JW**, Goodenow MM. Prevalence of Antiphospholipid Antibodies and Disease Manifestation in Children with Lupus Nephritis. *Pediatr Res* 37:398A:2371, 1995.
59. Massengill SF, **Sleasman JW**, Goodenow MM. T Cell Receptor (V β) Gene Utilization in SLE Nephritis. *Pediatr Res* 37:398A:2372, 1995.
60. **Sleasman JW**, Morton A, Skoda-Smith S, Goodenow MM. Memory CD4⁺ T Cells are the Predominant Population of HIV-1 Infected Lymphocytes in Neonates and Children. The 9th International Congress of Immunology, 23-29 July, 1995, San Francisco, CA, #3401, p574.

61. Perez EE, Barrie KA, Lamers SL, Farmerie WG, **Sleasman JW**, Dunn BM, Goodenow MM. HIV-Infected Mothers and Children Exhibit Natural Genetic Variation in HIV-1 Protease Alleles and in Protease Cleavage Sites in the Absence of Protease Inhibitors. Fourth Workshop on Viral Resistance, September 10-12, 1995, Annapolis, MD.
62. Perez EE, Leelamanit W, Barrie KA, Lamers SL, Farmerie WG, **Sleasman JW**, Dunn BM, Goodenow MM. Genetic and Functional Variation Occurs in HIV-1 Protease Alleles within Infected Mothers and Children in the Absence of Protease Inhibitors. The Third Conference on Retroviruses and Opportunistic Infections, January 18 - February 1, 1996, Washington, D.C.
63. *Leon B, Goodenow MM, Barrett DJ, **Sleasman JW**. Congenital Deficiency of CD4⁺ T Lymphocytes is Associated with the Progressive Loss of CD8⁺ T Cells. Clin Res 44:39A, 1996.
64. Mueller BU, Zuckerman J, Nelson RP Jr., **Sleasman JW**, Vora S, Saulis R, Higham C, Brouwers P, Jarosinski P, Lewis L, Sei S, Wood L, Zeichner St, Heath-Chiozzi M, Pizzuti D, Pizzo PA. A Phase I/II Study of the Protease Inhibitor Ritonavir (ABT-538) in Children with HIV Infection. International AIDS Conference.
65. Mueller BU, Smith S, **Sleasman JW**, Nelson RP, Meyer C, Deutsch P, Zwernsky S, Mistry G, Sei S, Wood, L, Zeichner S, Brouwers P, Jarosinski P, Lewis L. Pizzo PA. A Phase I/II Study of the Protease Inhibitor Indinavir (MK-639) in Children with HIV Infection. International AIDS Conference.
66. ***Sleasman JW**, Leon B, Hutcheson CE, Barrett DJ, Weiner RS, Miller AM. Haploidentical Bone Marrow Transplantation of Children with X-linked SCID Using Bone Marrow Depleted of T-Cells by Centrifugal Elutriation. Pediatr Res, 39:14A:69, 1996.
67. ***Sleasman JW**, Aleixo LF, Ryan K, Goodenow MM. Maternal HIV-1 Transmission is Associated with High Levels of Provirus in Blood CD4⁺ T Cells. Pediatr Res 39:185A:1096, 1996.
68. *Massengill SF, Ayoub EM, **Sleasman JW**. Necessity of Surveillance Renal Biopsies during Intravenous Cyclophosphamide (IVCYC) Therapy in Systemic Lupus Erythematosus (SLE) Nephritis. Pediatr Res 39:365A:2173, 1996.
69. *Massengill SF, **Sleasman JW**, Goodenow MM. Selective Expansion of T cell Receptor (V_β) Gene Families in SLE Nephritis. Pediatr Res 39:394A:2346, 1996.
70. Mueller B, Zuckerman J, Nelson RP Jr., **Sleasman JW**, et al: Update on the pediatric phase I/II study of the protease inhibitor ritonavir (ABT-538). 4th Conference on Retroviruses and Opportunistic Infections. January 22-26, 1997.
71. Tuttle DL, Anders C, Aleixo LF, Harrison J, **Sleasman JW**, Goodenow MM. Tissue and differentiation dependence of HIV-1: Productions by monocyte-derived macrophages (MDM). 4th Conference on Retroviruses and Opportunistic Infections. January 22-26, 1997.
72. Perez E, Mueller B, Pizzo P, Heath-Chiozzi M, Dunn B, **Sleasman JW**, Goodenow M. Emergence of variant protease alleles and upstream gag sequences in HIV-1 infected children enrolled in PR inhibitor Phase I/II clinical trials. 4th Conference on Retroviruses and Opportunistic Infections. January 22-26, 1997.
73. Walsek C, Edgerly M, Nelson RP, **Sleasman JW**, Jankelevich S, Chanock SJ, Schwartzentruber D, Jaffe ES, Kingma D, Pizzo PA, Mueller BU. The combination of retinoic acid and interferon-alpha for the treatment of lymphoproliferative disorders in children with immunodeficiency disorders. AIDS Malignancy Conference. 1997.

74. *Perez EE, Burkhardt B, Mueller B, Pizzo P, **Sleasman JW**, Goodenow MM. Genotypic resistance in HIV-1 protease emerges in infected pediatric patients with reduced virus burden and immune reconstitutions in response to HAART. Southern Society for Pediatric Research, Southern Regional Meetings, February 7-9, 1998.
75. *Leon BL, Mageed AA, Wingard J, **Sleasman JW**. Successful use of matched bone marrow transplantation in the treatment of Wiskott-Aldrich Syndrome and lymphoproliferative disease. Southern Society for Pediatric Research, Southern Regional Meetings, February 7-9, 1998.
76. Tuttle DL, Harrison JK, **Sleasman JW**, Goodenow MM. Increased surface expression of CCR5 on monocyte-derived macrophages mediate enhanced susceptibility. 5th Conference on Retroviruses and Opportunistic Infections, February 1-5, 1998.
77. ***Sleasman J**, Goodenow M, Nelson R, Wilfret D, Hutson A, Heath-Chiozzi, M, Pizzo P, Mueller B. Reconstitution of memory (CD45RO) and naive (CD45RA) CD4⁺ T cells following Ritonavir therapy in HIV- infected children with advanced disease. 5th Conference on Retroviruses and Opportunistic Infections, February 1-5, 1998.
78. Burkhardt B, Perez EE, Mueller B, Pizzo P, Dunn BH, **Sleasman JW**, Goodenow MM. Correction of immunological disorders with highly active antiretroviral therapies (HAART) of acute HIV-1 infection. 5th Conference on Retroviruses and Opportunistic Infections, February 1-5, 1998.
79. Jankelevich S, Mueller B, Smith S, Boss C, Zwierski S, Steinberg S, Wood L, Zeichner S, Serchuck L, **Sleasman JW**, Nelson R, Nguyen B-Y, Shadle C, Pizzo P, Yarchoan R. Long-term activity of Indinavir/ZDV/3TC in HIV-1 infected children: Results of a Phase I/II study. 5th Conference on Retroviruses and Opportunistic Infections. February 1-5, 1998.
80. Anders C, Acquino MJ, Miller G, **Sleasman JW**, Andiman WA, Goodenow MM. Replicative levels of primary HIV-1 isolates in monocyte derived macrophages (MDM) provide a marker for pathogenesis of M-tropic viruses. 5th Conference on Retroviruses and Opportunistic Infections. February 1-5, 1998.
81. **Sleasman JW**, Goodenow MM, Wilfert D, Hutson A, Pizzo P, Mueller B. Immunoreconstitution of CD45RA and CD45RO CD4⁺ T cells occurs independent of virologic response in HIV-1 infected children treated with ritonavir. Southern Society for Pediatric Research, New Orleans, LA, February 7-9, 1998.
82. **Sleasman JW**, Nelson RP Jr., Goodenow MM, Wilfert D, Hutson A, Heath-Chiozzi M, Baseler M, Zuckerman J, Pizzo PA, Mueller BU. Multiple lymphocyte lineages are involved in immunoreconstitution following ritonavir therapy in HIV-infected children. The Society of Pediatric Research, May 1-5, 1998.
83. Goodenow MD, Rose S, **Sleasman JW**. Temporal emergence of drug resistant HIV-1 occurs initially in the CD45RO subset of CD4 T cells and subsequently in CD45RA CD4 lymphocytes. International Conference on the Discovery and Clinical Development of Antiretroviral Therapies, December 7-12, 1998.
84. Goodenow MM, Perez EE, Bloom G, Lamers SL, **Sleasman JW**, Dunn BM. Complex genetic mechanisms contribute to emergence of virus resistance in response to therapy with protease inhibitors. 2nd International Workshop on HIV Drug Resistance & Treatment Strategies, June 24-27, 1998, Lake Maggiore, Italy.
85. Jankelevich S, Mueller B, Smith Mackall C, Zwierski S, Wood L, Zeichner S, Serchuck L, **Sleasman JW**, Nelson, R., Nguyen, B-Y., Shadle, C., Pizzo, P., Yarchoan, R.: Regeneration of CD4⁺45RA⁺ T lymphocytes in the presence of continued viral replication in HIV-infected children treated with 96 weeks of combination indinavir, 3TC and ZDV. 6th Conference on Retroviruses and Opportunistic Infections,

January 31 – February 4, 1999.

86. Nelson R, **Sleasman JW**, Cervia J, Scott G, Rutstein R, McKinney R, Nessley M, Hawe L, Nguyen B-Y. Indinavir (IDV) in combination with Stavudine (d4T) and Lamivudine (3TC) in HIV-infected children. 6th Conference on Retroviruses and Opportunistic Infections, January 31 - February 4, 1999.
87. Xie X, Tuttle D, Peden DW, **Sleasman JW**, Goodenow MM. CD4 T lymphocytes that coexpress CD45RO and CD45RA are the primary target cells for infection by HIV-1. 6th Conference on Retroviruses and Opportunistic Infections, January 31 - February 4, 1999.
88. Passalacqua DJ, **Sleasman JW**, Goodenow MM. Normal T cell research following tetanus immunization in X-linked agammaglobulinemia (XLA). *Pediatr Res* 45:12A:59, 1999.
89. Andiman WA, Aquino MJ, **Sleasman JW**, Goodenow MM. Growth in Primary Macrophage Cultures Not Syncytium Induction, Distinguishes Viral Isolates from Children with Rapidly Progressive HIV Disease from Those with Long Term Survival. *Pediatr Res* 45:155A:904, 1999. Society for Pediatric Research, May 1-4, 1999. San Diego, CA.
90. Burkhardt BR, Taylor GS, Nykiel G, Lee FE, Lamers SL, Tuttle DL, **Sleasman JW**, Goodenow MM. Tissue Specific segregation of HIV-1 in vertically infected patients as determined by long terminal repeat (LRT) and envelope (env) sequences. Cold Spring Harbor Retroviruses Meeting, May, 1999.
91. Goodenow MM, Rose SM, **Sleasman JW**. HIV-1 with wild-type protease persists in CD45RA CD4 T lymphocytes in the presence of drug resistant HIV-1 in the plasma. 4th International Workshop on HIV, Cells of Macrophage Lineage, and other Reservoirs. Florence, Italy. December 1-4, 1999.
92. Kimberlin DW, Jacobs RF, Powell DA, Corey L, Gruber WC, Rathore M, Bradley J, Diaz P, Kumar M, Arvin AM, Gutierrez, Shelton M, Weiner LB, **Sleasman JW**, et al: The Safety and Efficacy of High-Dose (HD) Acyclovir (ACV) in Neonatal Herpes Simplex Virus (HSV) Infections. *Pediatr Res*, 45:165A:963, 1999.
93. Rose S, Perez E, Peyser B, **Sleasman JW**, Goodenow MM. Pretherapy *gag/pol* HIV-1 Genotype Predicts Viral and Immune Response to Combination Therapy with Protease Inhibitors (PI) in PI-Naive Patients. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA January 30 - February 2, 2000.
94. Coberly CR, Tuttle DL, Xie XM, **Sleasman JW**, Goodenow MM. HIV is expressed preferentially by CD4 T-cells that coexpress CD45RO and CD45RA. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, California, January 30 – February 2, 2000.
95. **Sleasman JW**, Rose S, Perez E, Peyser B, Goodenow MM. Natural genetic polymorphisms in HIV-1 *gag/pol* impacts viral and immune response to antiretroviral therapy with protease inhibitors in naïve patients. Southern Society for Pediatric Research, New Orleans, Louisiana, February 17-19, 2000.
96. Saez-Llorens X, Nelson RP Jr., Emmanuel P, Wiznia A, Church J, **Sleasman J**, Van Dyke R, Richardson CG, Rosko C, Cutrell A, Hetherington S V. Ziagen (Abacavir, ABC) Combined with 3TC & ZDV is Safe and Effective Through 48 Weeks in HIV-1 Infected Antiretroviral Therapy-Experienced Children (CAN 3006). *Pediatric Research*, Boston, Massachusetts, May 12-16, 2000.
97. Tuttle DL, Briggs DR, Poole PP, Arnold JL, **Sleasman JW**, Goodenow MM. Changes in envelope alleles from HIV-1 quasispecies that emerge during protease inhibitor therapy in children. Cold Spring Harbor Laboratory Retroviruses Meeting, New York, New York, May 3-7, 2000.
98. Briggs DR, Burkhardt BR, Taylor GS, Tuttle DL, Goodenow MM, **Sleasman JW**. Phylogenetic identification and functional characterization of HIV-1 quasispecies from the thymus. Cold Spring Harbor

Laboratory Retroviruses Meeting, New York, New York, May 3-7, 2000.

99. Burkhardt BR, Oshier JT, Taylor GS, Lee FE, Tuttle DL, **Sleasman JW**, Goodenow MM. Promoter analysis of HIV-1 reveals distinct functional differences among tissue specific LTRs. Cold Spring Harbor Laboratory Retroviruses Meeting, New York, New York, May 3-7, 2000.
100. Kohler JJ, **Sleasman JW**, Goodenow MM. Effect of HIV on activated stat levels in target T-cell line. Immunology 2000, Seattle, Washington, May 12-16, 2000.
101. Kou ZC, Puhr JS, Rojas M, Goodenow MM, **Sleasman JW**. V β repertoire diversity and clonal expansion Within CD45RA and CD45RO T cells in healthy human infants. Immunology 2000, Seattle, Washington, May 12-16, 2000.
102. Saez-Llorens X, Nelson R, Emmanuel P, Wiznia A, Church J, **Sleasman JW**, Van Dyke R, Richardson C, Rosko C, Cutrell A, Hetherington S, for the CAN 3006 Study Team.: Ziagen (Abacavir, ABC) combined with 3 TC et ZDV is safe and effective through 48 weeks in HIV-1 infected therapy-experienced children (CAN 3006). Pediatric Academic Societies and American Academy of Pediatrics Joint Meeting, Boston, MA, May 12-16, 2000.
103. Kou ZJ, Puhr M, Goodenow MM, **Sleasman JW**. Progressive loss and restoration of the TCR V β repertoire diversity within CD8CD45RA T cells were associated with CD4 T lymphocytes in HIV infected children. 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February, 2001.
104. Rose S, Pomeroy S, Bloom G, **Sleasman JW**, Dunn B, Goodenow M. Polymorphisms in HIV-1 gag-pol influence both proteolytic processing and replication dynamics. 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February, 2001.
105. Kohler JJ, Tuttle D, Coberley C, **Sleasman JW**, Goodenow MM. HIV gp120 interaction with CD4 upregulates level of activated STATs in T-cell lines. 92nd Annual Meeting of the American Association for Cancer Research, New Orleans, LA, March, 2001.
106. Coberley CR, Tuttle DL, Xie X, Kou ZC, **Sleasman J W**, Goodenow MM. CD45RA⁺ CD45RO⁺ double positive CD4⁺ T-cells are targets for HIV-1 infection. Federation of American Societies for Experimental Biology 2001, Orlando, FL.
107. Kohler JJ, Coberley CR, Tuttle DL, **Sleasman JW**, Goodenow MM. HIV gp120 binding to CD4 results in activation of JAK/STAT pathway in T cell and monocytic cell lines. Federation of American Societies for Experimental Biology 2001, Orlando, FL.
108. Ghaffari G, Passalacqua DJ, Goodenow MM, **Sleasman J W**. Restoration of Functional Immunity in HIV-infected children who demonstrate high levels of viral replication and CD4 T Cell Reconstitution following HAART. Federation of American Societies for Experimental Biology 2001, Orlando, FL.
109. *Rose SL, Pomeroy S., O'Brien MPO, **Sleasman JW**, Dunn BM, Goodenow MM. HIV-1 Gag-Pol polymorphisms influence both proteolytic processing and replication dynamics. Cold Spring Harbor Laboratory Retrovirus Meeting, Cold Spring Harbor, NY, May, 2001.
110. Coberley CR, Tuttle DL, Xie X, Kou ZC, **Sleasman JW**, Goodenow MM. CD4 T-Cells that Co-express CD45R) and CD45RA are Targets for HIV-1 Infection. The American Society for Virology, Madison, WI, July, 2001.
111. *Rose, S.L. Pomeroy, S.M., O'Brien, O.O., **Sleasman, J.W.**, Dunn, B.M., Goodenow, M.M. Impact by protease inhibitor on evolution and function of *gag-pol* in pediatric patients. Second HIV-1 Drug Resistance Program's Symposium on Antiviral Drug Resistance, Chantilly, VA, December 9-12, 2001.

112. *Rose S, Perez E, Lamars S, **Sleasman JW**, Goodenow MM. Drug resistant replication competent HIV-1 occurs initially in the CD45RO subset of CD4 R cells and subsequently in CD4RA CD4 lymphocytes following antiretroviral therapy. 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, February 24-28, 2002.
113. *Coberley CR, Baker HV, Popp MP, **Sleasman JW**, Goodenow MM. Genomic analysis of sentinel genetic networks impacted by HIV-1 infection of monocyte derived macrophages. 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, February 24-28, 2002.
114. *Kou ZC, Puhr JS, Goodenow MM, **Sleasman JW**. Combination antiretroviral therapy corrects the disruptions in the TCR V β repertoire within CD45RA CD8 T cells of HIV-infected children. 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, February 24-28, 2002.
115. Kohler JJ, Tuttle DL, Coberley CR, **Sleasman JW**, Goodenow MM. Strain independent HIV gp120 activates STATs in T lymphocyte and monocytic cells. 2002 American Association of Cancer Research Annual Meeting, San Francisco, CA, April 8, 2002.
116. Burkhardt BR, Ghaffari G, Oshier JT, **Sleasman JW**, Goodenow MM. Functional analysis of tissue specific LTRS from primary HIV-1 display distinct promoter function in macrophages and PBMC. Cold Spring Harbor Laboratory Retrovirus Meeting, Cold Spring Harbor, NY, May 21-26, 2002.
117. Tuttle DL, Briggs DR, Arnold JL, Burkhardt BR, Poole PP, Jeffers LK, Bhatt D, **Sleasman JW**, Goodenow MM. HIV-1 Envelope V1 Determinants are critical for CXCR4-mediated infection of macrophages. Cold Spring Harbor Laboratory Retrovirus Meeting, Cold Spring Harbor, NY, May 21-26, 2002.
118. *Rose SL, Pomeroy SM, **Sleasman JW**, Goodenow MM. Viruses with protease resistance display selective fitness in macrophages. Cold Spring Harbor Laboratory Retrovirus Meeting, Cold Spring Harbor, NY, May 21-26, 2002.
119. Tuttle, D.L., LK Jeffers, DR Briggs, Sleasman **JW**, MM Goodenow. HIV-1 gp120 determinants in V1/V2 and V4/V5 contribute to CXCR4-mediated macrophage infection. Keystone Symposium on HIV Vaccine Development: Immunological and Biological Challenges, Banff, Alberta, Canada. 2003.
120. Kohler J, Gavegnano C, **Sleasman JW**, Goodenow MM. HIV gp120 and CD4 binding induces activation of STAT1, STAT3, and STAT5 in promonocytes and macrophages. 10th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, MA, February 10-14, 2003. Abstract # 389
121. Ghaffari G, Laiacona J, Passalacqua DJ, Goodenow MM, **Sleasman JW**. HIV-infected children displaying a discordant response to HAART (Viral Failure/Immune Successes) have immune and clinical outcomes similar to those of children who successfully suppress viral replication. 10th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, MA, February 10-14, 2003. Abstract # 882
122. Ghaffari G, Laiacona J, Passalacqua DJ, Goodenow MM, **Sleasman JW**. HIV-infected children who display CDRT cell reconstitution but fail to control viral replication following antiretroviral treatment have two year clinical outcomes similar to children who successfully control viral replication. Pediatric Academic Societies Meeting, Seattle, WA, May 3-6, 2003. *Pediatr Res* 53:333-A: 1899 (Apr) 2003.
123. Kou ZC, Sarzynski ME, Wu SS, Puhr JS, Goodenow MM, **Sleasman JW**. HIV infection disrupts the V β T cell receptor (TCR) repertoire of CD4 CD45RA CD4 T cells in infected children. *Pediatr Res* 53:13A:71 (Apr) 2003.
124. Lujan-Zilbermann J, Emmanuel PJ, Kamchaisatian W, Brown CL, **Sleasman JW**, Tangsinmankong N. The immune restoration syndrome in HIV-infected children. The 4th Pediatric Infectious Diseases

Society Meeting, San Diego, California, October 12-14, 2003.

125. Rose SL, Koch SJ, Pomeroy SM, Lamers SL, **Sleasman JW**, Goodenow MM. Segregation of HIV-1 protease genotypic resistance with blood compartments identifies the CD4+ and CD45RA T lymphocytes as long-lived viral reservoir. 1st International Workshop on HIV Persistence during Therapy. French West Indies, December 10-12, 2003. 1st International Workshop Abstract Book, Abstract # PP 2.4, p.70.
126. Rucker RP, **Sleasman JW**, Tangsinmankong N. Three week old male infant presents with epidermolysis bullosa and eosinophilic colitis. Health Sciences Center Research Day, University of South Florida, Tampa, FL, February 26, 2004. HSC Abstract Book, Abstract # 38
127. Siri D, **Sleasman JW**. DRESS syndrome from oxcarbazepine with response to high-dose corticosteroids. Health Sciences Center Research Day, University of South Florida, Tampa, FL, February 26, 2004. HSC Abstract Book, Abstract # 40
128. Pedroza-Martins L, Nguyen H, Ghaffari G, Kao Z, Goodenow MM, **Sleasman JW**. Patterns of immune reconstitution in HIV-infected children displaying a discordant response to combination antiretroviral therapy. 11th Conference on Retroviruses and Opportunistic Infections (CROI), San Francisco, CA, February 8-11, 2004. Abstract # 918 [CROI Abstract Book]
129. Koch S, Rose S, Pomeroy S, O'Brien, Dun B, **Sleasman JW**, Goodenow MM. Polymorphisms in HIV-1 *gag-pol* affect fitness in a cell-type-specific manner. 11th Conference on Retroviruses and Opportunistic Infections (CROI), San Francisco, CA, February 8-11, 2004. Abstract # 635 [CROI Abstract Book]
130. Tuttle D, Ghaffari G, Jeffers L, Briggs D, **Sleasman JW**, Goodenow MM. HIV-1 envelope determinants of CXCR4-mediated infection of macrophages: Utilization of CXCR4 by HIV-1 is cell-type-specific. 11th Conference on Retroviruses and Opportunistic Infections (CROI), San Francisco, CA, February 8-11, 2004. Abstract # 307 [CROI Abstract Book]
131. Yin L, Kou ZC, Goodenow MM, **Sleasman JW**. HIV infection affects TCR CDR3 V beta repertoire in CD4 CD45RA T lymphocytes in children. 11th Conference on Retroviruses and Opportunistic Infections (CROI), San Francisco, CA, February 8-11, 2004. Abstract # 218 [CROI Abstract Book]
132. Brown J, Coberley C, Kohler J, Craig H, **Sleasman JW**, Goodenow MM. Global perturbations of gene expression by HIV-1 in monocyte-derived macrophages: Synergistic induction and repression of genes mediating cell cycle arrest. 11th Conference on Retroviruses and Opportunistic Infections (CROI), San Francisco, CA, February 8-11, 2004. Abstract # 368 [CROI Abstract Book]
133. Rucker RP, **Sleasman JW**, Tangsinmankong N. Three week old male infant presents with epidermolysis bullosa and eosinophilic colitis. American Academy of Allergy, Asthma & Immunology, San Francisco, CA, March 19-21, 2004. J Allergy Clin Immunol 113:S294, 2004. Abstract # 1074
134. Zacharias D, Jones O, **Sleasman JW**. Decreased Expression of IRAK-M in the BXSB Mouse. Florida Allergy, Asthma & Immunology Society, Naples, Florida, June 11-13, 2004. Poster Presentation **First Prize**.
135. Siri D, **Sleasman JW**. DRESS Syndrome with Oxcarbazepine: Response to High-Dose Corticosteroids. Florida Allergy, Asthma & Immunology Society, Naples, Florida, June 11-13, 2004.
136. Goodenow MM, Rose SL, **Sleasman JW**. CD4 CD45RA T lymphocytes are long-lived cells that represent a latent reservoir for HIV-1 *in vivo*. XV International AIDS Conference, Bangkok Thailand, 11-16 July, 2004.

137. Hartel AS, **Sleasman JW**, Tangsinmankong N. Recurrent streptococcal meningitis in a child with heterozygous mannose-binding lectin mutation. American College of Allergy, Asthma & Immunology, Boston, Massachusetts, November 12-17, 2004. Abstract # 20, p.7, AAAAI Abstract Book, 2005.
138. Lavi RF, Tangsinmankong N, **Sleasman JW**, Day NK, Haraguchi S, Jones OY. Plasma cell myositis in a child with primary T cell deficiency. American College of Allergy, Asthma & Immunology, Boston, Massachusetts, November 12-17, 2004.
139. Sikora M, **Sleasman JW**, Tangsinmankong N. Treacher-Collins syndrome and associated common variable immunodeficiency. American College of Allergy, Asthma & Immunology, Boston, Massachusetts, November 12-17, 2004.
140. Siri DD, Brauer KS, Day NK, Tangsinmankong N, **Sleasman JW**. Mannose-binding lectin deficiency in children with recurrent infection. American College of Allergy, Asthma & Immunology, Boston, Massachusetts, November 12-17, 2004.
141. Brauer KS, Tangsinmankong N, **Sleasman JW**. Pneumocystis pneumonia outcomes in primary or secondary immunodeficiency. Southern Society for Pediatric Research (SSPR), February 24-25, 2005, New Orleans, Louisiana.
142. Brauer KS, Tangsinmankong N, Smith SS, **Sleasman JW**. Pulmonary outcomes are more severe among HIV-infected children with Pneumocystis Pneumonia than in children with primary immunodeficiency. 60th Annual Meeting of the American Academy of Allergy, Asthma & Immunology, March 19-23, 2005, San Antonio, Texas. J Allergy Clin Immunol 115:S87-333, 2005.
143. Ghaffari G, Tuttle D, Bunger J, **Sleasman JW**, Goodenow M. HIV-1 envelope gp120 determinants of CXCR4-mediated infection of macrophages. 12th Conference on Retroviruses and Opportunistic Infections (CROI), February 22-25, 2005, Boston, Massachusetts. Abstract # 214, p. 135, CROI Abstract Book, 2005
144. Hartel, A, **Sleasman JW**, Tangsinmankong N. Recurrent streptococcal meningitis in a child with heterozygous mannose-binding lectin mutation. 2005 Florida Allergy, Asthma & Immunology Society, Boca Raton, Florida, June 10-12, 2005.
145. Hartel A, **Sleasman JW**, Tangsinmankong T. Bullous pemphigoid in a newborn with evidence of maternal transmission. American College of Allergy, Asthma & Immunology (ACAAI), Anaheim, California, November 4 – 9, 2005.
146. Koch S, Gavegnano C, Pomeroy S, Lowe A, Rose S, **Sleasman JW**, Goodenow MM. Drug resistance and viral fitness. 12th Conference on Retroviruses and Opportunistic Infections (CROI), February 22-25, 2005, Boston, Massachusetts. Abstract # 685, p. 313, CROI Abstract Book, 2005. [Poster].
147. Koch S, O'Brien P, rose S, Pomeroy S, Dunn B, **Sleasman JW**, Goodenow MM. Novel determinants in HIV-1 *gag* regulate protease activity and viral fitness in a drug resistant variant. XIV International HIV Drug Resistance Workshop, Québec, Canada, June 7-11, 2005.
148. Kohler J, Brown J, Coberley C, **Sleasman JW**, Goodenow MM. HIV-1 induced changes in genetic networks involved in immune function, signal transduction, and a Th2-type shift in cytokine secretion in human macrophages. 12th Conference on Retroviruses and Opportunistic Infections (CROI), February 22-25, 2005, Boston, Massachusetts. Abstract # 280, p. 156, CROI Abstract Book, 2005.
149. Rodriguez C, Lujan J, Ghotikar M, Nguyen H, Prawer A, Pedroza L, Goodenow M, **Sleasman JW**, Emmanuel P. Compared to non-nucleoside reverse transcriptase inhibitors (NNRTI), protease inhibitor (PI) containing regimens results in greater immune reconstitution (IR) in children failing antiretroviral

therapy (ART). 45th ICAAC Meeting, New Orleans, Louisiana, September 21 – 24, 2005. **[Selected as a high-impact presentation]**

150. Siri DD, Gubernick SO, Sher MR, **Sleasman, JW**. Natural killer cell impairment in a patient with pachyonychia congenita. 61st Annual Meeting of the American Academy of Allergy, Asthma & Immunology, San Antonio, Texas, March 18-22, 2005. *J Allergy Clin Immunol* 115:S87-345, 2005.
151. Siri DD, Brauer KS, Thankavel B, Day NK, Tangsinmankong N, **Sleasman JW**. Mannose-binding lectin deficiency in children with recurrent infection. 2005 Florida Allergy, Asthma & Immunology Society, Boca Raton, Florida, June 10-12, 2005.
152. Yin L, Kou Z, Goodenow MM, **Sleasman JW**. Comparison of TCR CDR3 length distribution in CD4 and CD8 T cell naïve and memory subpopulations in healthy and HIV-infected children before and after ART. 12th Conference on Retroviruses and Opportunistic Infections (CROI), February 22-25, 2005, Boston, Massachusetts. Abstract # 755, p. 342, CROI Abstract Book, 2005.
153. Brown JN, Kohler JJ, **Sleasman JW**, Goodenow MM. Global gene expression profiles altered in primary macrophages by HIV-1 M-R5 but not T-X4 envelope. 13th Conference on Retroviruses and Opportunistic Infections (CROI), February 6 – 9, 2006, Denver, Colorado. CROI Abstract Book, Abstract #228 [Session 52]
154. Hartel A, **Sleasman JW**, Tangsinmankong T. Bullous pemphigoid in a newborn with evidence of maternal transmission. 62nd Meeting of the American Academy of Allergy, Asthma & Immunology, Miami Beach, Florida, March 3-7, 2006.
155. Koch S, Gavegnano C, Rose S, Pomeroy S, Dunn B, **Sleasman JW**, Goodenow MM. Gag mutations are dominant determinants of replicative fitness and drug sensitivity in a protease inhibitor-resistant HIV-1 variant. 13th Conference on Retroviruses and Opportunistic Infections (CROI), February 6 – 9, 2006, Denver, Colorado. CROI Abstract Book, Abstract # 611 [Session 103]
156. Lavi RF, Tangsinmankong N, Day NK, **Sleasman JW**. Case series of juvenile arthritis in two females with autosomal recessive agammaglobulinemia. 62nd Meeting of the American Academy of Allergy, Asthma & Immunology, Miami Beach, Florida, March 3-7, 2006.
157. McCubbin A, Haire RN, **Sleasman JW**. Progressive leukoencephalopathy in a female patient with congenital agammaglobulinemia. 2006 Annual Meeting of the American College of Allergy, Asthma & Immunology, Philadelphia, November 9-15, 2006. ACAAI Abstract Book, Abstract # P38, p.33.
158. Rodriguez C, Yin L, Koch S, Ghaffari G, Haraguchi S, Lowe A, Goodenow MM, **Sleasman JW**. Preservation of CD4 T cell production despite high HIV replication in children and adolescents receiving PI-containing ART. 13th Conference on Retroviruses and Opportunistic Infections (CROI), February 6 – 9, 2006, Denver, Colorado. CROI Abstract Book, Abstract # 671 [Session 112]
159. Sanka M, Nickeson RW, **Sleasman JW**, Dorsey MJ. Sweet syndrome – the youngest case presenting in a 12-day-old female. 2006 Annual Meeting of the American College of Allergy, Asthma & Immunology, Philadelphia, November 9-15, 2006. ACAAI Abstract Book, Abstract # P69, p.40.
160. Dowd M, Tangsinmankong N, Siri DD, Hartel AS, Brauer KS, Umeh IN, Day NK, **Sleasman JW**. Association between mannose-binding lectin deficiency and immunoglobulin subclass 4 deficiency in children with recurrent infections. 2007 Annual Meeting of the American Academy of Allergy, Asthma & Immunology, February 23 – 27, 2007, San Diego, California. *J Allergy Clin Immunol* 119:S71: Abstract # 278, 2007.
161. Bagg A, Gonzalez-Peralta R, Petrovic A, **Sleasman JW**. Novel CYBA gene mutation in a patient with chronic granulomatous disease associated with autoimmune hepatitis. 2007 Annual Meeting of the

American Academy of Allergy, Asthma & Immunology, February 23 – 27, 2007, San Diego, California. *J Allergy Clin Immunol* 119:S16: Abstract # 61, 2007.

162. Sanka M, Tangsinmankong N, Loscalzo M, **Sleasman JW**, Dorsey MJ. Complete DiGeorge syndrome due to CHD7 mutation. 2007 Annual Meeting of the American Academy of Allergy, Asthma & Immunology, February 23 – 27, 2007, San Diego, California. *J Allergy Clin Immunol* 119:S91: Abstract # 367, 2007.
163. Sriaroon P, Tangsinmankong N, Skoda-Smith S, Elder ME, **Sleasman JW**. Eosinophilic fasciitis associated with X-linked agammaglobulinemia: Report of two cases. 2007 Annual Meeting of the American Academy of Allergy, Asthma & Immunology, February 23 – 27, 2007, San Diego, California. *J Allergy Clin Immunol* 119:S90: Abstract # 353, 2007.
164. Rodriguez Carina, Yin Li, Morrow Matthew, Emmanuel Patricia, Goodenow Maureen, **Sleasman JW**, Sustained Increased Thymic Output and Decreased Immune Activation in Children and Adolescents with High Post Therapy Viral Loads while Receiving Protease Inhibitor – Containing ART. 2007 14th Annual Conference on Retroviruses and Opportunistic Infections, February 25 – 28, 2007, Los Angeles, California. CROI 2007 Abstract Book Abstract # 697 [Session 124], p. 324, 2007.
165. Goodenow Maureen, Ho Sarah, Gavegnano Christina, Coman Roxanna, Morrow Matthew, Dunn Ben, Fletcher Courtney, **Sleasman JW**. Dominant Effect of HIV-1 gag Polymorphisms and Target Cell Type on Replicative Fitness, Protease Processing and Drug Resistance. 2007 14th Annual Conference on Retroviruses and Opportunistic Infections, February 25 – 28, 2007, Los Angeles, California. CROI 2007 Abstract Book Abstract # 604 [Session 107], p. 289, 2007.
166. Yin L, McCready S, Lowe A, Oshier J, **Sleasman JW**, Goodenow MM. HIV-1 Env VIV2 length polymorphism predicts combination antiretroviral therapy outcome in HIV-infected children. 2007 14th Annual Conference on Retroviruses and Opportunistic Infections, February 25 – 28, 2007, Los Angeles, California. CROI 2007 Abstract Book Abstract # 734 [Session 129/130], p. 341, 2007.
167. Salemi M, Burkhardt B, Pomeroy S, Lowe A, Ghaffari G, **Sleasman JW**, Goodenow MM. Evolution of HIV-1 X4 phenotype in vivo in tissues and longitudinal PBMC sample is driven by episodic positive selection. 2007 14th Annual Conference on Retroviruses and Opportunistic Infections, February 25 – 28, 2007, Los Angeles, California. CROI 2007 Abstract Book Abstract # 257 [Session 59], p. 158, 2007.
168. Dorsey MJ, Petrovic A, Morrow MR, Dishaw LJ, **Sleasman JW**. FOXP3 expression following bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning. The Federation of Clinical Immunology Societies (FOCIS) 2007, June 7-11, 2007, San Diego, California. [Poster Session F.86]. *Clin Immunol* 123:S189-206, 2007, Abstract #F.86, pS43
169. Rudy B, **Sleasman JW**, Kapogiannis B, Wilson C, Bethel J, Cunningham C and the Adolescent Trials Network for HIV/AIDS Interventions 015 Study Team. Short cycle therapy in adolescents following continuous therapy with established viral suppression: The impact on viral load suppression. 2008 15th Annual Conference on Retroviruses and Opportunistic Infections, February 3-6, 2008, Boston, Massachusetts. CROI 2008 Abstract Book Abstract # 580 [Session 96], p. 269, 2008.
170. Salemi M, Gray RR, Koch S, **Sleasman JW**, Goodenow MM. A new algorithm to detect HIV-1 intra-patient recombinant sequences and investigate the role of recombination in the emergence of CXCR4-using viral variants. 2008 15th Annual Conference on Retroviruses and Opportunistic Infections, February 3-6, 2008, Boston, Massachusetts. CROI 2008 Abstract Book Abstract # 258 [Session 52], p. 147, 2008.
171. Brown JN, Kohler J, Coberley C, **Sleasman JW**, Goodenow MM. HIV-1 activates macrophages independent of toll-like receptors, a potential mechanism for dysregulation of innate immunity. 2008 15th

Annual Conference on Retroviruses and Opportunistic Infections, February 3-6, 2008, Boston, Massachusetts. CROI 2008 Abstract Book Abstract # 382 [Session 65/66], p. 191, 2008.

172. Haraguchi S, Ho S, Pomeroy S, Goodenow MM, **Sleasman JW**. HIV-1 replicative capacity in the thymus maps to p2/p7^{NC} and the flap region of gag-pol. Keystone Symposia Global Health Series, HIV Pathogenesis (X8), March 27 – April 1, 2008, Fairmont Banff Springs, Banff, Alberta, Canada. Keystone Symposia 2008 Abstract Book, Abstract # 203, p 210.
173. Brown JN, Kohler, JJ, Coberley, CR, **Sleasman JW**, Goodenow MM. HIV-1 activates macrophages independent of toll-like receptors, a potential mechanism for dysregulation of innate immunity. Keystone Symposia 2008 Abstract Book, Abstract # 113, p 193.
174. Woodward J, Dorsey M, **Sleasman JW**. Selective B cell lymphopenia associated with systemic amyloidosis in a patient with familial Mediterranean fever. 2008 Meeting of the Federation of Clinical Immunology Societies (FOCIS 2008), June 5 – 9, Boston, Massachusetts.
175. Caplan B, Rodriguez C, Morrow M, Potter O, **Sleasman JW**. Immune reconstitution (IR) in late-presenting (LT) *HIV-1* vertically-infected children treated with antiretroviral therapy (ART) is similar to that of age-matched *HIV-1* vertically-infected children treated since infancy. 46th Annual Meeting of Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27 – 30, 2008, San Francisco, California.
176. **Sleasman JW**, Church JA, Stein MR, Wasserman RL, Robak T. Efficacy and safety of IgPro10 in primary immunodeficiency and chronic immune thrombocytopenic purpura. American Society of Health-System Pharmacists. 43rd Midyear Clinical Meeting, December 7 – 11, 2008, Orlando, Florida.
177. Walsh CJ, Leggett SR, Strohhenn K, Pierce RH, **Sleasman, JW**. Effects of in vitro Brevetoxin Exposure on Apoptosis and Cellular Metabolism in a Leukemic T Cell Line (Jurkat) Mar. Drugs 2008, 6, 291-307.
178. Wallet M, Saporta, S, Koch S, **Sleasman JW**, Goodenow MM. Reduced Pathogenesis by High Levels of Drug-resistant HIV Replication 2009 16th Annual Conference on Retroviruses and Opportunistic Infections, February 8-11, 2009, Montreal, Canada. CROI 2009 Abstract Book Abstract # 309 [Session 61], p. 167, 2009.
179. Sriaroon P, Morrow M, Hudey S, Goodenow M, **Sleasman JW**, CD27+B220 B cell subpopulation is decreased in Human immunodeficiency Virus Disease on therapy Common Variable Immune Deficiency and Systemic Lupus Erythematosus. Keystone Symposia: B Cell in Context, Taos, New Mexico. February 28, 2009.
180. Dorsey MJ, Morrow, MR, **Sleasman JW**. Differential Expression of Naïve Phenotype T Regulatory Cells in Allergic Asthmatics vs. Health Age-matched Controls. American Academy of Allergy, Asthma & Immunology, 2009 Annual Meeting March 13-17, 2009.
181. Duff CM, Faulkner E, Schirm Z, Lang J, Rodriguez CA, **Sleasman JW**. Effective Use of Subcutaneous Immune Globulin (SCIG) for an Infant with X-linked Agammaglobulinemia (X-LA). American Academy of Allergy, Asthma & Immunology, 2009 Annual Meeting March 13-17, 2009.
182. Chinratanapisit S, Wallet MA, Saporta SR, Ghaffari G, Rodriguez CA, Goodenow MM, **Sleasman JW**. Measurements of Plasma Lipopolysaccharide (LPS), Endotoxin Core IgM Antibody (EndoCAb), Soluble CD14 (sCD14), TNFa, and Soluble CD62L (sCD62L) Levels to Assess Microbial Translocation and Immune Activation in HIV-Infected Children and Adolescents. American Academy of Allergy, Asthma & Immunology, 2009 Annual Meeting March 13-17, 2009.

183. Sriaroon P, Morrow MR, Hudey SN, Goodenow MM, **Sleasman JW**. Memory CD27⁺ B220⁻ B Cell Subpopulation is Decreased in Both Systemic Lupus Erythematosus (SLE) and Common Variable Immune Deficiency (CVID). American Academy of Allergy, Asthma & Immunology, 2009 Annual Meeting March 13-17, 2009.
184. McMahan DF, Watkins SM, Reich A, Kellogg DA, Gonzalez BE, **Sleasman JW**. A Cluster of Cases of Cutaneous Rashes in Swimmers Exposed to Freshwater Spring-fed Rivers in Northern Florida. American Academy of Allergy, Asthma & Immunology, 2009 Annual Meeting March 13-17, 2009.

INVITED PRESENTATIONS AT REGIONAL AND NATIONAL MEETINGS (2003 – 2009)

November 18-21, 2003, AIDS Symposium, “The Interaction between HIV and the Immune System: Implications in Treatment and Vaccine Development,” Charleston, South Carolina

February 12-15, 2004, Management of Tiny Babies Conference, “Immaturity of the Neonatal Immune System: Bioterrorism and its Implications for the Neonate,” Orlando, Florida

April 9-10, 2004, Florida Allergy, Asthma and Immunology Society, “Evaluating the Child with Suspected Immunodeficiency Disease,” St. Augustine, Florida

May 22, 2004, Grant Writing Workshop, “The Nuts and Bolts of Implementing a Clinical Research Protocol,” University of South Florida College of Public Health, Tampa, Florida

June 11-13, 2004, Florida Allergy, Asthma and Immunology Society (FAAIS) Meeting, “Evaluating the Child with Suspected Immunodeficiency Disease,” Naples, Florida

September 18, 2004, Florida Suncoast Symposium, “My Child is always sick; does he need an Immunology Evaluation,” Sarasota, Florida

March 22, 2005, American Academy of Asthma, Allergy, and Immunology Meeting, “Optimal Use Clinical Immunology Tests,” San Antonio, Texas

June 10-12, 2005, Florida Allergy, Asthma & Immunology Society (FAAIS), Boca Raton, Florida
 “The Use and Abuse of IVIG Therapy,” “Laboratory Interpretation of Clinical Immunology Tests,”

August 6, 2005, Florida Society for Health-System Pharmacists, Inc, “The Use and Abuse of Intravenous Gammaglobulin Therapy,” Orlando, Florida

October 11-15, 2005, FANNP National Neonatal Symposium, “Immunological Disorders in the Neonate,” Clearwater, Florida

November 5, 2005, Florida Pediatric Alumni Association Meeting, HIV/AIDS Update, “Evaluation of Child with Primary Immune Deficiency,” Hilton University of Florida Conference Center, Gainesville, Florida

January 11, 2006, Faculty Development Seminar, “Getting Started in Clinical Research,” University of South Florida/All Children’s Hospital, St. Petersburg, Florida

January 28, 2006, Lyme Symposium, ‘Current Controversies in Pediatric Lyme disease,’ All Children’s Hospital, St. Petersburg, Florida

February 21, 2006, Children’s Hospital of Philadelphia Silver Lecture, “The Taming of HIV in Children and Adolescents,” Philadelphia, PA

April 6-7, 2006, AAAAI/ACAAI Board Certification Course, "HLA and Transplantation," Chicago, IL

June 9-12, 2006, Robert A. Good Immunology Symposium, "Taming HIV in Children," St. Petersburg Beach, FL

November 15-17, 2006, AIDS Symposium, "Taming HIV," Medical University of South Carolina
Charleston, SC

February 24-28, 2007, AAAAI Meeting, "Pathogenesis and Consequences of Secondary Immunodeficiency in
AIDS," San Diego, California

April 2, 2007, GMS Lecture Series, "The Nuts and Bolts of Implementing a Clinical Research Protocol,"
University of South Florida, Tampa, Florida

April 16, 2007, ACAAI Board Review Course, "HLA and Transplantation," Chicago, Illinois

May 4-5, 2007, SIPAID – Advances in Immune Regulation Conference, "Discordant viral and immune outcomes
in HIV-infected children receiving antiretroviral therapy," Tampa, Florida

June 9, 2007, Florida Allergy, Asthma and Immunology Society (FAAIS) Meeting, "CVID including Non-
Infectious Manifestations," Sarasota, Florida

September 11, 2007, Central Florida Pediatric Society, "Evaluation of the Child with Suspected
Immunodeficiency," Orlando, Florida

January 18-19, 2008, Council on Primary Immune Deficiency Disease, "How-to Guide for Initiating Vivaglobin®,"
Dallas, Texas

April 17, 2008, AAAAI/ACAAI Certification/Maintenance of Certification Board Review Course, "HLA and
Transplantation," Chicago, Illinois

March 10-11, 2009, Council on Primary Immune Deficiency Disease, "Overview on IVIG" Tucson, Arizona

April 2-3, 2009, Council on Primary Immune Deficiency Disease, Raleigh, North Carolina

May 11-14, 2009, Council on Primary Immune Deficiency Disease, "How-to Guide for Initiating Vivaglobin®,"
Madrid, Spain

June 18-20, 2009 FAAIS Annual Meeting, "HIV -1 Infection" Orlando, Florida

August 21, 2009 Council on Primary Immune Deficiency Disease, "Overview on IVIG", Las Vegas, Nevada

September 3, 2009 Council on Primary Immune Deficiency Disease, "Overview on IVIG", Malabar, Florida